<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sporadic lymphangioleiomyomatosis: Treatment and prognosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sporadic lymphangioleiomyomatosis: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Sporadic lymphangioleiomyomatosis: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francis X McCormack, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nishant Gupta, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geraldine Finlay, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1516340072"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder that mostly afflicts women. The term sporadic LAM is used for patients with LAM who do not have tuberous sclerosis complex (TSC), while TSC-LAM refers to LAM that occurs in patients with TSC. The management of LAM is generally based upon supportive care, use of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> to slow progression of respiratory impairment, and prevention or treatment of complications [<a href="#rid1">1,2</a>].</p><p>The management, monitoring, and prognosis of sporadic LAM and its complications are reviewed here. The epidemiology, pathogenesis, clinical presentation, and diagnostic evaluation of sporadic and TSC-LAM are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">"Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"</a>.)</p><p class="headingAnchor" id="H2615773410"><span class="h1">GENERAL MEASURES</span><span class="headingEndMark"> — </span>Given the complexities and multisystem nature of LAM, we encourage patient referral to centers with expertise in this disorder for shared care between LAM experts and local pulmonologists. (See <a class="local">'Additional resources'</a> below.)</p><p class="headingAnchor" id="H3969534977"><span class="h2">Supportive care</span><span class="headingEndMark"> — </span>Several supportive measures are useful in managing patients with LAM:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of cigarette smoking</strong> – Patients with LAM should be advised to avoid cigarette smoking and passive exposure to tobacco smoke, given the potential for accelerating disease progression  (<a class="graphic graphic_table graphicRef74402" href="/z/d/graphic/74402.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration of COVID-19, influenza, and pneumococcal vaccines</strong> – Similar to patients with other chronic lung diseases, vaccination against common respiratory pathogens should be performed in all LAM patients  (<a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a> and  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplemental oxygen</strong> – Supplemental oxygen is indicated in those who desaturate (ie, pulse oxygen saturation [SpO<sub>2</sub>]) at rest  (<a class="graphic graphic_table graphicRef76543" href="/z/d/graphic/76543.html" rel="external">table 2</a>), during exercise, and/or with sleep. While resting SpO<sub>2</sub> is routinely performed during clinic visits by most subspecialists, clinicians should have a low threshold to perform nocturnal oximetry or a formal six-minute walk test to evaluate the need for oxygen supplementation. (See  <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">"Overview of pulmonary function testing in adults", section on 'Six-minute walk test'</a>.)</p><p></p><p class="bulletIndent1">One retrospective study of 25 patients with LAM and mild to moderate lung function impairment reported significant nocturnal desaturations in 56 percent of patients, despite a normal resting SpO<sub>2</sub> [<a href="#rid3">3</a>]. While the long-term risk of isolated nocturnal desaturation is unknown, we prescribe supplemental oxygen for sleep-related hypoxemia when the SpO<sub>2</sub> drops below 88 percent for more than 5 percent or at least five minutes of the sleep duration, the patient has symptoms or signs reasonably associated with desaturation (eg, pulmonary hypertension, erythrocytosis), and no other cause (eg, obstructive sleep apnea) is identified. (See  <a class="medical medical_review" href="/z/d/html/1445.html" rel="external">"Long-term supplemental oxygen therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1442.html" rel="external">"Portable oxygen delivery and oxygen conserving devices"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exercise and pulmonary rehabilitation</strong> – We routinely refer symptomatic patients with LAM for pulmonary rehabilitation, particularly those whose activities are limited by dyspnea [<a href="#rid4">4,5</a>]. One study reported reduced physical activity in 34 women with LAM compared with healthy volunteers and age-matched women with chronic obstructive pulmonary disease (COPD) [<a href="#rid4">4</a>]. Another study of 40 patients with LAM reported rehabilitation was safe in those with a low physical activity level and led to improved exercise capacity, dyspnea, quality of life, and muscle strength [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/2786.html" rel="external">"The benefits and risks of aerobic exercise"</a> and  <a class="medical medical_review" href="/z/d/html/1463.html" rel="external">"Pulmonary rehabilitation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutrition</strong> – Patients with LAM should eat a healthy diet and maintain a normal weight. While traditionally women with LAM were advised to avoid eating foods containing phytoestrogens (eg, soy), there is no evidence that this strategy affects disease progression in LAM, and dietary restrictions based on the hormonal influences of food are not generally advised. A systematic review of the effects of soy and phytoestrogens in breast cancer concluded that soy does not have significant estrogenic activity in humans and is safe in the quantities consumed in a traditional Japanese diet [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/1440.html" rel="external">"Malnutrition in advanced lung disease"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychosocial support</strong> – Many patients experience fear, anxiety, and depression during the course of their illness, which is often most pronounced soon after diagnosis. Proactive psychosocial support from clinicians, chaplains, mental health and palliative care providers, and LAM advocacy and support groups can help prevent debilitating mental health consequences. (See  <a class="medical medical_review" href="/z/d/html/2195.html" rel="external">"Psychosocial issues in advanced illness"</a> and  <a class="medical medical_review" href="/z/d/html/86307.html" rel="external">"Palliative care for adults with nonmalignant chronic lung disease"</a> and <a class="local">'Additional resources'</a> below.)</p><p></p><p class="headingAnchor" id="H2197268335"><span class="h2">Bronchodilators and inhaled glucocorticoids</span><span class="headingEndMark"> — </span>In patients with airflow obstruction on spirometry, particularly those with demonstrable reversibility, inhaled bronchodilator therapy may provide symptomatic relief [<a href="#rid7">7,8</a>], despite the absence of an effect on dynamic hyperinflation [<a href="#rid7">7,9</a>]. Some patients appear to respond better to inhaled beta-agonists and others to inhaled anticholinergic agents. An empiric trial of each is appropriate with a view to chronic maintenance therapy for patients with symptomatic benefit. The efficacy of inhaled glucocorticoids has not been formally examined. Their use is typically reserved for patients who are believed to have concomitant asthma. (See  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/558.html" rel="external">"Beta agonists in asthma: Acute administration and prophylactic use"</a> and  <a class="medical medical_review" href="/z/d/html/1450.html" rel="external">"Role of muscarinic antagonist therapy in COPD"</a>.)</p><p></p><p class="headingAnchor" id="H2047251944"><span class="h2">Minimizing risk of complications</span></p><p class="headingAnchor" id="H840592231"><span class="h3">Air travel</span><span class="headingEndMark"> — </span>Patients should be assessed for the potential risk associated with an in-flight pneumothorax and/or oxygen desaturation. In general, most LAM patients can undertake air travel safely.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumothorax</strong> – Patients with LAM are reported to have a small but increased risk of spontaneous pneumothorax during flight (1 to 2 per 100 flights). Decisions regarding the safety of air travel are influenced by several factors including the burden of cysts, degree of lung function impairment, history of pneumothoraces, prior pleurodesis, and extent of cardiopulmonary reserve in the event of an in-flight pneumothorax. In general, air travel is considered to be safe in most patients with LAM [<a href="#rid10">10,11</a>]. However, patients with reduced pulmonary reserve or high-risk features (eg, high burden of cysts, severe lung function impairment, history of multiple pneumothoraces) may prefer to seek alternative modes of travel. Patients with unexplained or new onset chest pain or dyspnea should be evaluated with a chest radiograph to rule out pneumothorax prior to air travel. Additional details regarding air travel and pneumothorax are described separately. (See  <a class="medical medical_review" href="/z/d/html/6705.html" rel="external">"Pneumothorax and air travel"</a>.)</p><p></p><p class="bulletIndent1">This approach is based upon data from retrospective series:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one series of 281 patients with LAM, the risk of a new pneumothorax on chest radiograph or computed tomography (CT) was no different in those who traveled by air (3 percent, 1.1 per 100 flights) compared with those who traveled by land (2 percent, 0.5 per 100 trips) [<a href="#rid10">10</a>]. A new pneumothorax was more likely in patients with large cysts and more severe disease, regardless of the mode of travel. Over one-half of the patients had evidence of chronic pneumothorax.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a questionnaire-based evaluation derived from 276 patients with LAM who reported air travel (estimated total of 454 flights), most women traveled without serious adverse events [<a href="#rid11">11</a>]. However, a significant proportion reported air travel-related dyspnea (14 percent), chest pain (12 percent), pneumothorax (4 percent; most identified by chest radiograph), and oxygen desaturation (8 percent). The rate of pneumothoraces was 2.2 events per 100 flights.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In another questionnaire-based study of LAM patients in the European Union, five patients reported a spontaneous pneumothorax from 178 flights, amounting to a per-flight pneumothorax risk of 2.8 percent. However, in contrast to the prior studies that focused on events in the immediate peri-travel period, any pneumothorax detected within 30 days of travel was deemed secondary to air travel in this study, leading to a higher estimate of the risk [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supplemental oxygen</strong> – When assessing the need for supplemental oxygen during flight, the principles of management should be similar to those with other lung diseases. (See  <a class="medical medical_review" href="/z/d/html/1448.html" rel="external">"Evaluation of patients for supplemental oxygen during air travel", section on 'Pulmonary lymphangioleiomyomatosis'</a> and  <a class="medical medical_review" href="/z/d/html/6705.html" rel="external">"Pneumothorax and air travel"</a>.)</p><p></p><p class="headingAnchor" id="H1693646158"><span class="h3">Exogenous estrogen</span><span class="headingEndMark"> — </span>LAM exacerbations have been associated with the use of exogenous systemic estrogen (eg, birth control pills, hormone replacement, ovulation induction agents for assisted reproduction)  (<a class="graphic graphic_table graphicRef89046" href="/z/d/graphic/89046.html" rel="external">table 3</a>), and exposure to these agents should be minimized (eg, for egg harvest) or avoided. Low-dose topical estrogen creams, tablets, and rings used for atrophic vaginitis are generally felt to be safe in survivors of breast cancer and, by extrapolation, in patients with LAM [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H373198914"><span class="h3">Pregnancy and birth control</span><span class="headingEndMark"> — </span>Clinicians should inform women with LAM about the increased risks associated with pregnancy including pneumothorax, chylothorax, lung disease progression, and hemorrhage into angiomyolipomas (AMLs) [<a href="#rid1">1,14-24</a>]. Although some patients have tolerated pregnancy without long-term consequences, many patients do develop LAM-related complications, and there are no known factors that reliably predict risk. Because of the uncertainty, many women with LAM choose to avoid pregnancy. For patients who choose to become pregnant, those with excellent lung function and a stable disease course at baseline are better positioned to assume risk, while those with severe lung impairment or rapidly declining disease, recurrent pneumothorax or chylothorax, or a significant burden of AML may have more limited reserves and greater potential for complications.</p><p>This approach is based upon limited objective data regarding the effects of pregnancy on LAM disease course. Small retrospective series report that between one- and two-thirds of women with LAM have been pregnant at some point in their lifetime [<a href="#rid20">20,25</a>], but in most studies it is unclear if LAM was present during pregnancy. In a study of 16 pregnant women with LAM, the mean forced expiratory volume in one second (FEV<sub>1</sub>) decreased from 77 percent predicted before pregnancy to 64 percent predicted after pregnancy [<a href="#rid26">26</a>]. Diffusing capacity decreased from 66 to 57 percent predicted. Five patients developed pneumothorax (bilateral in four) during pregnancy, which was consistent with the 25 to 30 percent prevalence of pneumothorax during pregnancy noted in a survey-based assessment of women with LAM [<a href="#rid24">24</a>]. Mechanistic target of rapamycin (mTOR) inhibitors were withdrawn at or before pregnancy in the three patients for whom they were prescribed. Ten women underwent cesarean section while six had spontaneous vaginal delivery. After pregnancy, FEV<sub>1</sub> continued to decline in many patients, 10 of whom required <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> treatment and one of whom required lung transplantation. This observational study affirms the above-mentioned assertions that pregnancy can accelerate the rate of disease progression in certain women with LAM.</p><p>For women who choose to avoid pregnancy, our approach to birth control is the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Options for birth control</strong> – Selecting a method for contraception should be done in conjunction with a subspecialist; it is typically individualized and dependent upon patient preferences. Estrogen-containing oral contraceptives should be avoided since exogenous estrogens are thought to exacerbate the disease [<a href="#rid27">27-30</a>]. Potential options for contraception include abstinence, vasectomy of partner, tubal ligation, progesterone-only subcutaneous implants, intrauterine devices (IUDs; eg, copper or low-dose drug-eluting IUDs), oral or injectable <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a>, and barrier protection  (<a class="graphic graphic_table graphicRef89046" href="/z/d/graphic/89046.html" rel="external">table 3</a> and <a class="graphic graphic_figure graphicRef119765" href="/z/d/graphic/119765.html" rel="external">figure 2</a>). (See  <a class="medical medical_review" href="/z/d/html/5459.html" rel="external">"Contraception: Counseling and selection"</a> and  <a class="medical medical_review" href="/z/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection"</a> and  <a class="medical medical_review" href="/z/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a> and  <a class="medical medical_review" href="/z/d/html/5461.html" rel="external">"Contraception: Progestin-only pills (POPs)"</a> and  <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">"Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge"</a> and  <a class="medical medical_review" href="/z/d/html/5463.html" rel="external">"External (formerly male) condoms"</a>.)</p><p></p><p class="bulletIndent1">Emergency contraception (eg, <a class="drug drug_general" data-topicid="104542" href="/z/d/drug information/104542.html" rel="external">levonorgestrel</a>) should not be routinely used as the sole method of birth control; however, in rare circumstances the benefits of avoiding an unwanted pregnancy may outweigh the one-time use of emergency contraception. (See  <a class="medical medical_review" href="/z/d/html/5475.html" rel="external">"Emergency contraception"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – For women who choose to become pregnant, comanagement with a maternal fetal medicine specialist is advised. The risk of fetal anomalies or spontaneous abortions is unknown but does not appear to be increased. Since sporadic LAM is not inheritable, genetic counseling is typically not necessary. (See  <a class="medical medical_review" href="/z/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a>.)</p><p></p><p class="bulletIndent1">Surveillance with pulmonary function testing is advised prior to pregnancy and as needed during gestation to investigate worsening symptoms in addition to ongoing monitoring for complications of LAM. While there is no consensus, the choice of delivering by cesarean section or vaginally (with or without regional anesthesia and instrumental assistance) should be individualized; however, in settings where anesthesia and assistance can be instituted, vaginal delivery is often the preferred option provided there are no other indications for cesarean section.</p><p></p><p class="bulletIndent1">Successful pregnancies have been reported in women taking <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> (for LAM or for immune suppression following transplant) [<a href="#rid31">31-33</a>]. However, sirolimus has been reported to result in early fetal demise in animal studies and, as such, the use of sirolimus is typically avoided during pregnancy. It is unknown whether sirolimus is secreted in breast milk, and as such breast-feeding while taking sirolimus is not advised.</p><p></p><p class="headingAnchor" id="H2151552941"><span class="h3">Others</span><span class="headingEndMark"> — </span>Deep-sea diving, sky diving, and bungee jumping could theoretically increase the risk of pneumothorax, so patients are advised against participating in these activities.</p><p>Rare LAM cells have been isolated from the peripheral blood of untreated patients [<a href="#rid34">34-36</a>]. However, no reports of transmitting LAM via blood have been published to date and it is unclear whether or not patients with LAM can safely donate blood [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H818158703"><span class="h1">TREATMENT OF PULMONARY LAM</span><span class="headingEndMark"> — </span>The key treatment for parenchymal lung disease due to sporadic LAM is inhibition of the mechanistic target of rapamycin (mTOR) signaling with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. In general, sirolimus is indicated for symptomatic patients with abnormal lung function (forced expiratory volume in one second [FEV<sub>1</sub>] &lt;70 percent predicted), evidence of rapidly progressive disease, or problematic chylous accumulations. It is important to consider the baseline trajectory of illness in making treatment decisions (eg, postmenopausal women may have a slower rate of decline) because the drug has toxicities and continuous exposure is required for durable benefit. Lung transplantation may be the only option for patients with advanced LAM or in those with disease that is refractory to mTOR inhibitor treatment.</p><p>Several guidelines have been published [<a href="#rid1">1,2,38</a>]. Our strategy for the treatment of LAM is in accordance with the American Thoracic Society and Japanese Respiratory Society (ATS/JRS) Clinical Practice Guidelines [<a href="#rid2">2</a>] and French guidelines from the Orphan Lung Network [<a href="#rid38">38</a>] but differs slightly from that of the European Respiratory Society (ERS) [<a href="#rid1">1</a>] because sentinel publications regarding <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> were not available during the preparation of the ERS guidelines. Given the complexities and multisystem nature of LAM, we encourage consultation with or referral to centers with expertise in this disorder when treatment with mTOR inhibitors is being considered. (See <a class="local">'Additional resources'</a> below.)</p><p class="headingAnchor" id="H2859911392"><span class="h2">Normal or mildly impaired lung function</span><span class="headingEndMark"> — </span>For most patients with normal or mildly impaired pulmonary function, we suggest supportive measures, treatment of complications as they arise, and monitored observation, rather than treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. While there is no agreed upon threshold, we consider those with a FEV<sub>1</sub> ≥70 percent predicted as having mild disease and those who have a FEV<sub>1</sub> within the standard confidence limits as having normal function. (See <a class="local">'General measures'</a> above and <a class="local">'Treatment of complications'</a> below and <a class="local">'Monitored observation'</a> below.)</p><p>Some exceptions exists:</p><p class="bulletIndent1"><span class="glyph">●</span>Regardless of lung function, we administer <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> to patients with LAM who also have evidence of complications known to be sirolimus responsive (eg, symptomatic chylous accumulations, AMLs &gt;4 cm in diameter). (See <a class="local">'Chylothorax and chylous ascites'</a> below and <a class="local">'Angiomyolipomas'</a> below and <a class="local">'Other lymphatic disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In those with normal or mildly impaired lung function, we also consider therapy in those with substantial disease burden or rapidly progressive disease. Thus, on an individualized basis, we and other experts occasionally administer <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> in a select group of patients who have normal or mildly reduced FEV<sub>1</sub> when one or more of the following is present:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of abnormal and/or progressive lung dysfunction due to LAM:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Rapidly declining FEV<sub>1</sub> (eg, FEV<sub>1</sub> loss of greater than 100 mL per year based on three or more separate post bronchodilator measurements over 12 to 18 months)</p><p class="bulletIndent3"><span class="glyph">-</span>Elevated residual volume (&gt;120 percent predicted) sufficient to impact symptoms or vital capacity</p><p class="bulletIndent3"><span class="glyph">-</span>Reduced diffusing capacity for carbon monoxide (DLCO; &lt;lower limit of normal)</p><p class="bulletIndent3"><span class="glyph">-</span>Heavy burden of cysts (ie, cysts involving more than one-third of the lungs)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of abnormal gas exchange thought to be due to LAM:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Exercise-induced desaturation (saturation drops by 4 percent or more with ambulation)</p><p class="bulletIndent3"><span class="glyph">-</span>Resting hypoxemia (partial arterial pressure of oxygen &lt;70 mmHg; 9.3 kPa)</p><p></p><p>When considering <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> treatment in patients with mild LAM, clinicians should be aware that the evidence to support it is based on extrapolation from a sicker LAM population and the rationale that the potential benefits of early rather than late therapy outweigh the risks of drug-induced toxicity. A discussion with the patient is critical so that a shared, well-informed decision can be made regarding therapy. A randomized, multicenter trial to determine the efficacy of early, low-dose sirolimus administration in patients with normal or mildly reduced FEV<sub>1 </sub>is in progress (Multicenter Interventional LAM Early Disease [MILED] Trial, NCT03150914). (See <a class="local">'Sirolimus (first line)'</a> below.)</p><p class="headingAnchor" id="H1928617125"><span class="h3">Monitored observation</span><span class="headingEndMark"> — </span>Patients with sporadic LAM who have normal or mild lung function impairment are assessed by serial pulmonary function testing (PFT) at regular intervals to monitor the rate of disease progression and to assist in decision making with regards to treatment initiation with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. The role of serial measurements of vascular endothelial growth factor-D (VEGF-D) is unknown.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical evaluation and pulmonary functions tests</strong> – It is estimated that at least 12 to 18 months of quarterly FEV<sub>1</sub> measurements are required to obtain an accurate slope of change [<a href="#rid39">39</a>]. Thus, we typically perform a formal clinical assessment and PFTs (postbronchodilator spirometry, lung volumes, and DLCO) at 6 and 12 months and postbronchodilator spirometry alone during interval visits at three and nine months. A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fanushkapalipana.shinyapps.io%2Ftestapp_v2%2F&amp;token=uoVYwkWWF9HLbmae%2F1ZnyWgGojs42K7u1iUFNH9G0PtBaKHaM7H6GbelAvPN6hGkov7Da0Bl6SNWsLXpaOeL0g%3D%3D&amp;TOPIC_ID=107652" target="_blank">prediction model</a> can help estimate future lung function decline using a few easily obtained variables and may aid clinical decision making [<a href="#rid40">40</a>]. There is no agreed upon definition of fast versus slowly declining lung function, but in our practice, we consider those with an FEV<sub>1</sub> decline of ≥100 mL per year (roughly three to four times the normal rate of FEV<sub>1</sub> decline in adults) as "fast decliners" and consider initiation of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> in this subgroup. In contrast, if lung function declines slowly or is stable, testing intervals can be extended to every 6 or 12 months until a definite indication to treat with sirolimus is reached. (See <a class="local">'Normal or mildly impaired lung function'</a> above and <a class="local">'Moderate to severe lung function impairment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CT</strong> – There is no consensus with regards to performing routine serial high-resolution CT (HRCT) chest in patients with LAM. The potential health risk of cumulative radiation exposure (1.5 to 7 millisievert [mSv] per examination) is weighed against the likelihood that repeat imaging will change management. Thus, for sporadic LAM patients with normal or mildly reduced lung function, we obtain additional HRCT only to investigate new symptoms suggestive of disease progression or complications.</p><p></p><p class="bulletIndent1">Most centers possess the ability to perform a low-dose chest CT, similar to that performed for lung cancer screening [<a href="#rid41">41</a>]. Using this protocol, radiation exposure from a CT scan can be reduced by approximately 50 percent compared with HRCT and resolution is likely adequate for disease monitoring purposes in most patients. CT radiation dose can be lowered to 0.4 mSv (dose equivalent to that from posteroanterior and lateral chest radiography) using model-based iterative reconstruction techniques without compromising the accuracy of LAM cyst quantification [<a href="#rid42">42</a>]. However, the technology and expertise for this type of dose reduction procedure is not yet available at most centers. It is important to note that the utility of low-dose CT chest for disease monitoring in patients with LAM, and other cystic lung diseases, has not been systematically evaluated. Monitoring of AMLs is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'Treatment'</a> and <a class="local">'Angiomyolipomas'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VEGF-D</strong> – VEGF-D should be measured at baseline, if not already performed during the diagnostic evaluation. This approach is based upon evidence that baseline levels of serum VEGF-D may predict decline off therapy and response to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid43">43-45</a>]. These data are discussed below. (See <a class="local">'Prognostic factors'</a> below.)</p><p></p><p class="headingAnchor" id="H1087120726"><span class="h2">Moderate to severe lung function impairment</span><span class="headingEndMark"> — </span>For most patients with sporadic LAM who have moderate to severe lung function impairment, as defined by an FEV<sub>1</sub> &lt;70 percent predicted, we recommend treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> rather than observation. <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> is an alternative in those who do not tolerate sirolimus. Both agents belong to the mTOR inhibitor family, and sirolimus (also known as rapamycin) has been approved for the treatment of LAM by the US Food and Drug Administration (FDA), the European Medicines Agency, and regulatory agencies in many other countries [<a href="#rid46">46</a>]. While sirolimus stabilizes lung function and improves some measures of quality of life and functional performance, it is a suppressive rather than curative therapy and lung function decline typically resumes once the drug is stopped [<a href="#rid47">47</a>].</p><p>In postmenopausal women who do not have historical lung function data available, but who have a reasonable respiratory reserve (eg, FEV<sub>1</sub> &gt;50 percent predicted), or in asymptomatic patients, it may be appropriate to establish a baseline rate of disease progression using serial lung function measurements over a 6-to-12 month period prior to initiating <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. The rationale for this approach is that the trajectory of lung function decline is typically slower in this population, although direct evidence to support this approach is limited.</p><p class="headingAnchor" id="H3188308930"><span class="h3">Sirolimus (first line)</span></p><p class="headingAnchor" id="H3792533977"><span class="h4">Dose and duration</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Initial dosing</strong> – We typically start <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> at 1 mg orally once daily and measure trough levels (20 to 28 hours after the last dose) 7 to 14 days after drug initiation, targeting a serum level of ≤10 ng/mL. In the pivotal randomized trial that demonstrated the efficacy of sirolimus (MILES trial), sirolimus levels were titrated to a range between 5 and 15 ng/mL, the median sirolimus level in MILES was 7 ng/mL, and levels in excess of 10 ng/mL were rare [<a href="#rid47">47</a>]. While many experts initiate sirolimus at 2 mg/day, following the approach employed in the only randomized trial that has demonstrated efficacy [<a href="#rid47">47</a>], we find that 1 mg/day is often sufficient to stabilize lung function [<a href="#rid48">48</a>], even when trough sirolimus levels are below 5 ng/mL. However, in patients who are declining very rapidly (ie, &gt;100 mL/year) or have limited reserves, we feel it is prudent to start with 2 mg/day and consider titrating back to 1 mg/day once stability is achieved. Additional support for targeting a trough level of &lt;10 ng/mL, rather than the 5 to 15 ng/mL classically published in literature, has also been described in patients taking sirolimus following lung transplantation [<a href="#rid49">49,50</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Subsequent dosing</strong> – Subsequent dosing varies depending upon several factors, such as clinical response, adverse effects, drug interactions, and intercurrent illnesses. We only escalate the <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> dose beyond 1 mg daily in patients who fail to achieve the desired clinical response, regardless of whether the trough sirolimus level achieves a predetermined target. Our philosophy is that when administering potentially life-long therapy to young women, it is prudent to use the lowest effective dose to optimize long-term safety. In contrast, we often decrease the dose, transiently or permanently, in patients experiencing adverse effects that affect patient safety, comfort, quality of life, or compliance. Sirolimus should be held temporarily (ie, one to two weeks before and one to two weeks after) for intercurrent illnesses involving fever or deep infection and for elective surgeries due to its immunosuppressant and delayed wound-healing effects. Evidence to support this dosing strategy and monitoring for adverse effects and a clinical response are discussed below. (See <a class="local">'Efficacy'</a> below and <a class="local">'Monitoring adverse effects'</a> below and <a class="local">'Monitoring clinical response'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration</strong> – <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> is a suppressive rather than curative therapy; upon discontinuation, lung function decline generally resumes at pretreatment rates. Thus, we typically continue sirolimus indefinitely, or for as long as it is tolerated, and try to minimize interruptions. Our experience has been that sirolimus has a favorable safety profile and results in continued stabilization of lung function in most patients [<a href="#rid47">47,51-54</a>]. An observational study (MIDAS, NCT02432560) is ongoing and aims to investigate the long-term safety and efficacy of sirolimus in patients with LAM. Data to support this strategy are discussed below. (See <a class="local">'Efficacy'</a> below.)</p><p></p><p class="bulletIndent1">Whether or not <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> should be discontinued after menopause, a life transition that can be associated with a reduction in the rate of lung function decline, is unknown. Consideration of a trial of discontinuation involves shared decision making with the patient and vigilant monitoring off therapy.</p><p></p><p class="headingAnchor" id="H2307111473"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Support for the use of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> in this population is based upon one randomized study [<a href="#rid47">47</a>] that is corroborated by smaller observational studies, post hoc data, and clinical experience [<a href="#rid36">36,45,47,48,51,52,55-60</a>]. Data that support sirolimus efficacy for parenchymal disease in LAM are discussed in this section, while data that support the use of sirolimus in lymphatic disease are discussed below. (See <a class="local">'Other lymphatic disease'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>The effect of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> on lung function was compared with placebo in a randomized trial of 89 patients with moderate to severe lung function impairment (FEV<sub>1</sub> &lt;70 percent predicted) due to LAM (MILES) [<a href="#rid47">47</a>]. Sirolimus was initially administered orally at 2 mg/day and adjusted to maintain a blood trough level between 5 and 15 ng/mL. After 12 months, the FEV<sub>1</sub> was stable in the sirolimus group, but had declined in the placebo group (+1 versus -12 mL/month); improvements in the forced vital capacity (FVC; +8 versus -11 mL/month), functional residual capacity, quality of life, and functional performance were also noted in the sirolimus group compared with placebo. However, DLCO and six-minute walk distance did not improve. Patients were followed off treatment for an additional 12 months, during which time pulmonary function in the sirolimus group declined at the same rate as that in the placebo group.</p><p></p><p class="bulletIndent1">Importantly, there was considerable variation in the response to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> with some patients exhibiting significant improvements in lung function and a smaller proportion who continued to decline on therapy, albeit at a slower rate than placebo. In a post hoc analysis of the MILES trial, patients who had an elevated baseline VEGF-D declined more rapidly on placebo and had a more favorable physiologic response to sirolimus [<a href="#rid43">43,45</a>]. (See <a class="local">'Prognosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low-dose regimens may also confer similar improvement in lung function comparable with those reported in MILES. As an example, one case series of 15 LAM patients reported that <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> administered to target a trough ≤5 ng/mL resulted in improved FEV<sub>1</sub> (-115 versus +128 mL/year) and FVC (-101 versus +190 mL/year) when compared with rates recorded prior to therapy [<a href="#rid48">48</a>]. Mean sirolimus trough levels of as low as 2 ng/mL were associated with disease stability; our clinical experience with the efficacy of low-dose sirolimus is similar.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data suggest that the effect is maintained while on long term <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> and may lead to improved survival [<a href="#rid52">52,54,60</a>]. One retrospective study reported an eight-year cumulative survival rate of 90 percent in patients treated with sirolimus compared with 78 percent in those not taking sirolimus despite worse baseline lung function and symptoms in the sirolimus treatment group (eg, FEV<sub>1</sub> 64 versus 86 percent) [<a href="#rid60">60</a>]. In a retrospective series of 12 patients with LAM followed for up to five years on sirolimus, a significant reduction in the annual rate of decline in FEV<sub>1</sub> (+0.3 versus -1.4 percent predicted) and annual increase in cyst size (0.3 versus 1.8 percent) was reported [<a href="#rid52">52</a>]. Similarly, an open-label study of sirolimus administered for two years in 63 women with LAM reported overall stabilization of FEV<sub>1</sub> and FVC and improvement in lung function [<a href="#rid54">54</a>]. The safety profile was favorable in each of these studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Limited data report that patients with a rapid decline in lung function also benefit. Among those with rapidly declining FEV<sub>1</sub> (&gt;3 percent predicted per year) or diffusion capacity (&gt;5 percent predicted per year) prior to therapy, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> therapy at doses similar to those in MILES resulted in stabilization or improvement in these parameters when administered for up to 5.4 years (mean 2.6 years) [<a href="#rid51">51</a>]. However, resolution of chylous effusions on sirolimus in some patients may have resulted in overestimation of the effect of sirolimus on FEV<sub>1</sub> slope before and after treatment initiation. (See <a class="local">'Other lymphatic disease'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A post-hoc analysis of the MILES data has shown that <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> is an effective therapy for LAM regardless of underlying menopausal status (pre- versus postmenopausal), race (Asian versus White), LAM subtype (tuberous sclerosis complex [TSC] versus sporadic), baseline FEV<sub>1</sub>, or the presence or absence of reversible airflow obstruction [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1">The mechanism of action of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> in LAM relates to its activity as an inhibitor of the mTOR complex, which is inappropriately activated by loss of TSC gene function in LAM  (<a class="graphic graphic_figure graphicRef58634" href="/z/d/graphic/58634.html" rel="external">figure 3</a>). A few studies have reported a reduction of LAM cells in both blood and on tissue biopsy in response to therapy [<a href="#rid34">34,61</a>]. Detailed discussion of mTOR and the pathogenesis of LAM is provided separately. (See  <a class="medical medical_review" href="/z/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Tuberous sclerosis gene mutations'</a>.)</p><p></p><p class="headingAnchor" id="H94377460"><span class="h4">Monitoring adverse effects</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> is generally well tolerated, especially when administered in lower doses now commonly used for LAM; although some patients discontinue sirolimus due to side effects.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Adverse effects, which are generally dose-related, commonly include stomatitis, diarrhea, hyperlipidemia, dyspepsia, nausea, and acneiform rash. Less common adverse effects include lower extremity swelling, renal insufficiency, hypertension, drug interactions, infection, delayed wound healing, susceptibility to latent neoplasms, pneumonitis, allergies, and hematologic abnormalities (eg, anemia, thrombocytopenia, leukopenia, lymphopenia) [<a href="#rid62">62</a>]. Adverse effects from <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> tend to be most common in the few months following drug initiation and tend to decrease over time [<a href="#rid45">45,54</a>].</p><p></p><p class="bulletIndent1">Mouth ulcers, acne, nausea, and diarrhea are usually easily treated with local therapies or over-the-counter medications. Topical applications of corticosteroids are the mainstay for treatment of mouth ulcers resulting from use of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> [<a href="#rid63">63-65</a>]. Over-the-counter acne medications, usually containing <a class="drug drug_general" data-topicid="8811" href="/z/d/drug information/8811.html" rel="external">benzoyl peroxide</a> and/or salicylic acid, are reasonable first-line agents to treat acne resulting from sirolimus.</p><p></p><p class="bulletIndent1">If hypercholesterolemia develops, it can usually be controlled with dietary modification and/or an oral statin. Profound hypertriglyceridemia has been reported in a few patients and can result in pancreatitis [<a href="#rid66">66</a>]. Anemia, leukopenia, lymphopenia, and thrombocytopenia have been reported but are rare at lower doses (eg, 1 mg/day) and usually not profound enough to warrant discontinuing the drug. (See  <a class="medical medical_review" href="/z/d/html/4549.html" rel="external">"Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/4570.html" rel="external">"Hypertriglyceridemia in adults: Management"</a>.)</p><p></p><p class="bulletIndent1">Drug interactions can alter <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> levels (eg, antihypertensives, antibiotics, antiseizure medications); in such cases, remeasuring trough levels after 7 to 14 days on new medications with known interactions or using an alternative medication without interaction is prudent. A list of interactions can be identified using the<a class="external" href="%2Fdrug-interactions%2F%3Fsource%3Dresponsive_home%23di-disclaimer&amp;data=05|01|Geraldine.Finlay%40wolterskluwer.com|4633cb82337f488fbb1c08dad9fc1f30|8ac76c91e7f141ffa89c3553b2da2c17|0|0|638061974122588494|Unknown|TWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D|3000|||&amp;sdata=%2BGQxacOvEJMeW6unDZU4KuVzGS1G2VHlyuTpxg2sJNk%3D&amp;reserved=0" target="_blank"> drug interactions</a> program included within UpToDate.</p><p></p><p class="bulletIndent1">Infections due to the immunosuppressant function of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> are a concern. However, one review of 11 studies reported that although infections occurred in patients treated with sirolimus, there was no statistical difference in the rate of respiratory infections, including severe infections when compared with placebo [<a href="#rid67">67</a>]. In addition, some studies suggest that mTOR inhibitors may actually enhance immunity in older adults and reduce viral infections [<a href="#rid68">68,69</a>].</p><p></p><p class="bulletIndent1">Rare but serious side effects include pneumonitis and latent neoplasms (eg, lymphomas). <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> pneumonitis did not occur in the MILES trial [<a href="#rid47">47</a>] but has been reported as a rare occurrence in other trials and case reports [<a href="#rid54">54</a>]. Sirolimus pneumonitis is typically reversible with either dose reduction or discontinuation. In cases where respiratory failure develops, corticosteroid therapy has been used to accelerate resolution [<a href="#rid54">54</a>]. Risk of latent malignancy is a class effect of immunosuppressant therapies but remains only a theoretical risk in the case of monotherapy with mTOR inhibitors since it has not been reported in LAM patients to our knowledge.</p><p></p><p class="bulletIndent1">The optimal approach to detecting sirolimus-associated opportunistic infections or inflammatory pneumonitis is unknown. In general, these are rare events (&lt;1 percent). We do not routinely perform surveillance chest CT scans but rather obtain chest imaging based upon development of symptoms of cough, shortness of breath, or fever. We do not generally prescribe prophylactic antibiotics to prevent opportunistic infections such as <em>Pneumocystis jirovecii</em> pneumonia (PJP) unless patients have other immunosuppressive conditions or treatments, such as poorly controlled diabetes, an underlying immunodeficiency disorder, or chronic steroid use.</p><p></p><p class="bulletIndent1">Allergies to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> are uncommon but can be life threatening. Desensitization regimens have been employed in some cases [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory monitoring</strong> – We measure complete blood counts, fasting lipids and glucose, liver and renal function, and urine protein at baseline, and this panel plus <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> trough levels monthly for three months and then at three month intervals for the first year [<a href="#rid47">47</a>]. For those on 2 mg of sirolimus or higher, we generally continue obtaining these laboratory tests every three months indefinitely. In patients on low-dose sirolimus (&lt;2 mg/day) who have no adverse effects over the first 12 months of therapy, we often extend the interval for laboratory studies to twice per year.</p><p></p><p class="headingAnchor" id="H458996219"><span class="h4">Monitoring clinical response</span><span class="headingEndMark"> — </span>Patients should be assessed for adverse effects of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> within the first two to four weeks and periodically thereafter (see <a class="local">'Dose and duration'</a> above and <a class="local">'Monitoring adverse effects'</a> above). Once desired levels have been achieved and the drug is demonstrated to be well tolerated, patients should also be clinically assessed for a symptomatic and physiologic response. Our approach is the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary function tests</strong> – Postbronchodilator spirometry (FEV<sub>1</sub> and FVC) is typically obtained every three to six months, and full PFTs including DLCO and lung volumes should be obtained at least once per year. Reduction in the rate of decline in spirometric values relative to those measured prior to treatment is the primary metric of treatment response and should be plotted in all patients. In treated patients with limited pretreatment lung function data, we consider rates of FEV<sub>1</sub> decline &lt;50 mL/year to represent disease stabilization. Although diffusion capacity is not known to be improved by <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, it should be measured since disease progression can occasionally manifest as reduction in DLCO disproportionate to spirometric values.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – We typically do not perform routine chest CT scans to follow disease progression or treatment response, although practice varies considerably. Our approach is based upon the avoidance of cumulative radiation exposure and the lack of evidence to support CT as a validated radiologic biomarker. However, we perform chest CT in those with an atypical course or features and for other clinical indications (eg, a precipitous decrease in PFTs, suspected pneumonitis, or radiographically occult pneumothorax). CT evidence of reduced gas trapping and changes in lung texture surrounding cysts have been reported as outcomes of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> therapy [<a href="#rid71">71-73</a>], but further study is needed to determine whether quantifying lung volumes or cyst volume ("cyst volume percent"), using standard- or low-dose CT, is of clinical value [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">In contrast, reduction in size of AMLs on abdominal imaging is a measurable response to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> that some experts consider a therapeutic biomarker in patients with LAM. (See  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a> and  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong> – Although treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> results in a reduction in VEGF-D levels [<a href="#rid45">45,47,75</a>], further studies are needed to determine whether serial VEGF-D testing can be used to facilitate decisions regarding dose and duration of therapy or as a surrogate biomarker to predict future response to therapy. We generally obtain baseline VEGF-D levels prior to initiating sirolimus. While there are no guidelines on the measurement of VEGF-D levels while on treatment with sirolimus, we typically obtain serum VEGF-D levels three months after starting sirolimus in order to assess the effect of treatment. Once serum VEGF-D has reached a nadir (typically three to four months following initiation of sirolimus), the VEGF-D monitoring intervals can be extended to every 12 months. If dose escalation is contemplated in the future, we believe that incremental reductions in VEGF-D upon up-titration of sirolimus can be used as a barometer of the degree of mTOR pathway suppression; that is, if VEGF-D drops further at higher doses, the pathway was incompletely suppressed. The potential value of VEGF-D as a prognostic marker is discussed below. (See <a class="local">'Prognostic factors'</a> below.)</p><p></p><p class="bulletIndent1">VEGF-C is not routinely measured, although one study reported that VEGF-C levels decrease following treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, and returned toward baseline when sirolimus is held, similar to the pattern of VEGF-D responses [<a href="#rid76">76</a>]. In another retrospective study, cancer antigen-125 (CA-125), which was elevated in 25 percent of patients with LAM, decreased following treatment with sirolimus [<a href="#rid77">77</a>]. However, it remains investigational as a marker of therapeutic response. Several other biomarkers are being investigated [<a href="#rid78">78</a>].</p><p></p><p class="headingAnchor" id="H1799648437"><span class="h3">Everolimus (second line)</span><span class="headingEndMark"> — </span>Anecdotally, rare patients who do not tolerate or respond to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> may respond to <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. A theoretical advantage of everolimus over sirolimus is that it has a shorter half-life (30 versus 62 hours) [<a href="#rid79">79</a>], which may make it a more attractive therapy for those in whom more rapid washout is needed (eg, approaching lung transplantation or other surgery). However, whether this feature decreases the risk of dehiscence and delayed wound healing is unknown and no comparative trials have been performed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – While <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> is not approved for sporadic LAM, the dose used in the only clinical trial was 2.5 mg mg/day increasing to 10 mg/day, targeting a trough level of 5 to 15 ng/mL [<a href="#rid80">80</a>]. There were significant side effects at the higher doses of everolimus, however, and in practice doses of greater than 5 mg/day are rarely used in sporadic LAM. As with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, many experts attempt to determine the lowest effective dose that maintains lung function stability by starting at a low dose and titrating the drug over time to the lowest level that maintains stability in postbronchodilator FEV<sub>1</sub> measured every three months or so. Dose equivalence studies for sirolimus to everolimus conversions have not been established for sporadic LAM, but organ transplant studies suggest a ratio of 1:1 to 1:2. (See  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Role of mTOR inhibitor therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Data that support <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> use in LAM are derived from one open-label study in LAM patients as well as from studies of treatment of TSC-related tumors. Collectively, the results suggest that everolimus and <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> likely have similar efficacy:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a multicenter, open-label safety study, 24 women with pulmonary LAM were treated with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> (2.5 mg/day increasing to 10 mg/day) for 26 weeks, targeting a trough level of 5 to 15 ng/mL [<a href="#rid80">80</a>]. The FVC remained stable, while the FEV<sub>1</sub> improved from baseline with a mean increase of 114 mL and the six-minute walk distance improved by 47 meters. Improvements in lung function were sustained during the extension phase (up to 60 weeks of treatment). Adverse events were similar to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>; serious adverse events included peripheral edema, pneumonia, pneumonitis, cardiac failure, and <em>Pneumocystis jirovecii</em> infection. There were five patients who stopped the study drug due to adverse effects, all while taking the highest dose (10 mg/day). We do not endorse the routine use of everolimus at this dose in patients with LAM.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> is approved for the treatment of AMLs, central nervous system tumors, and epilepsy due to TSC. Durable benefit with long-term administration (eg, greater than two years) in TSC has been described [<a href="#rid81">81</a>]. (See <a class="local">'Other lymphatic disease'</a> below and  <a class="medical medical_review" href="/z/d/html/90017.html" rel="external">"Renal angiomyolipomas (AMLs): Management"</a> and  <a class="medical medical_review" href="/z/d/html/16902.html" rel="external">"Tuberous sclerosis complex: Management and prognosis", section on 'Role of mTOR inhibitor therapy'</a>.)</p><p></p><p class="headingAnchor" id="H4235875798"><span class="h3">Other</span><span class="headingEndMark"> — </span>For patients who do not respond to or who cannot tolerate the mTOR inhibitors, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, options are limited to supportive care, treatment of complications, clinical trials, and lung transplantation. Although not routinely recommended, hormonal manipulation (eg, gonadotropin-releasing hormone [GnRh] agonists, aromatase inhibitors) is sometimes administered in mTOR inhibitor refractory or intolerant patients, especially those who have symptoms or complications that are exacerbated in a cyclical manner during the menstrual cycle [<a href="#rid2">2</a>]. (See <a class="local">'Statins, doxycycline, hormone manipulation, hydroxychloroquine, celecoxib, resveratrol'</a> below.)</p><p class="headingAnchor" id="H235446075"><span class="h2">Refractory disease</span><span class="headingEndMark"> — </span>Some patients (probably less than 10 percent) continue to have progressive lung function decline despite the use of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. In this population, alternative explanations for lack of treatment response such as those listed below should be ruled out. (See <a class="local">'Investigating progressive dyspnea'</a> below.)</p><p>For those with progression due to worsening parenchymal disease, options include increasing the dose of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> toward the upper end of the therapeutic range (ie, to serum levels of 10 to 15 ng/mL), a trial of substitution with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, participation in clinical trials, and referral for lung transplantation. Although not routinely recommended, hormonal manipulation (eg, GnRh agonists, aromatase inhibitors, etc) is sometimes attempted, especially in those with menstrual cycle related variation in respiratory symptoms. Choosing among these options is dependent upon factors including patient preference and pulmonary reserve. (See <a class="local">'Clinical trials'</a> below and <a class="local">'Lung transplantation'</a> below and <a class="local">'Everolimus (second line)'</a> above and <a class="local">'Statins, doxycycline, hormone manipulation, hydroxychloroquine, celecoxib, resveratrol'</a> below.)</p><p class="headingAnchor" id="H4168421505"><span class="h3">Clinical trials</span><span class="headingEndMark"> — </span>Several clinical trials for LAM patients involving novel agents or combination therapies involving mTOR inhibitors and other agents have either been completed or are in progress. Detailed information regarding these studies can be accessed at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3Dlymphangioleiomyomatosis&amp;token=JKcSmCXgdKvw9eDYrJDw9oeiz6hQPhqvolXEeStyEFMZoxMS8ktK%2BcvVvauZctRupS1MrSHzJrGBnTLLytyNM7qFY66gUuI%2FTQNKdcgyoB4%3D&amp;TOPIC_ID=107652" target="_blank">Clinicaltrials.gov</a> or <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thelamfoundation.org%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUrxDyepJycAgsqoy5dhzs0bCF1D5kRrCZy7y52FO2E76b&amp;TOPIC_ID=107652" target="_blank">The LAM Foundation website</a>. Examples of investigational therapies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Interferon-gamma or beta</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anti-estrogen-tamoxifen [<a href="#rid82">82</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Promoters of autophagy (eg, <a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">hydroxychloroquine</a>) [<a href="#rid83">83</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Matrix metalloproteinase inhibitors (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>) [<a href="#rid84">84</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tyrosine kinase inhibitors (eg, saracatinib, <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">imatinib</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inhaled <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prostaglandin inhibitors (<a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">Celecoxib</a> or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>) [<a href="#rid85">85</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Statins (<a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">Simvastatin</a>) [<a href="#rid86">86</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resveratrol [<a href="#rid87">87</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10064" href="/z/d/drug information/10064.html" rel="external">Letrozole</a> [<a href="#rid82">82</a>]</p><p></p><p class="headingAnchor" id="H2837799194"><span class="h3">Lung transplantation</span><span class="headingEndMark"> — </span>Patients with LAM may eventually require lung transplantation because of progressive respiratory failure. Selection criteria and lung transplantation type are similar to those for other chronic lung diseases. The presence of a renal AML, other complications of LAM, prior pleurodesis [<a href="#rid88">88</a>], or TSC are not generally considered to be contraindications to lung transplantation. The outcomes following lung transplantation in LAM appear to be better than patients with other chronic lung diseases [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Referral</strong> – While firm criteria for referral for lung transplantation evaluation have not been set, reasonable thresholds include New York Heart Association (NYHA) functional class III or IV (ie, symptoms with minimal exertion or severe limitation with symptoms at rest), rapidly progressive respiratory impairment, FEV<sub>1</sub> &lt;30 percent of predicted, and hypoxemia at rest. (See  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection", section on 'General guidelines'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – Several series have reported results of lung transplantation for LAM [<a href="#rid90">90-99</a>]. The largest series analyzed outcomes in 134 LAM patients registered with the United States United Network for Organ Sharing (UNOS) who underwent lung transplantation between January 2003 and June 2017 [<a href="#rid89">89</a>]. The majority of patients (109/134, 81 percent) underwent bilateral sequential lung transplantation. The median time spent on the transplant wait list was 257 days, which was reduced to 148 days after the introduction of the lung allocation score in 2005. The median post lung transplant survival in LAM was 12 years, with 1-, 5-, and 10-year survival rates of 94, 73, and 55 percent, respectively. These survival rates exceed those of other disease groups transplanted in the same time frame (p&lt;0.0001). Similar post-transplantation survival outcomes have been reported from a study evaluating 57 LAM patients who underwent lung transplantation in Japan, with 1-, 3-, and 5-year survival rates of 87, 82, and 74 percent, respectively [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1">Lung function and quality of life after transplant are improved compared with patients with advanced LAM [<a href="#rid93">93</a>]. The main causes of death after transplant are similar to other lung diseases and include primary graft dysfunction (early) and infection and bronchiolitis obliterans (late) [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/z/d/html/4663.html" rel="external">"Primary lung graft dysfunction"</a> and  <a class="medical medical_review" href="/z/d/html/4659.html" rel="external">"Lung transplantation: An overview"</a>.)</p><p></p><p class="bulletIndent1">Disease-related complications in one study of 34 patients included [<a href="#rid90">90</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extensive pleural adhesions in 18 patients, leading to intraoperative hemorrhage in four patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pneumothorax in the native lung in 6 of the 27 patients who received a single lung transplant.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postoperative chylothorax in three patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Recurrent LAM in the allograft occurred in one patient; this complication has also been noted in other reports [<a href="#rid95">95,99,101,102</a>]. Recurrent LAM in the transplanted lung manifests as cellular aggregates derived from recipient cells, suggesting hematogenous migration of LAM cells as a mechanism of recurrent disease [<a href="#rid101">101</a>]. This metastatic mechanism is also supported by the relative absence of cystic change in an oligemic lung segment of a LAM patient with otherwise diffuse cystic lung disease [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of </strong><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a><strong> before and after transplant</strong> – Special considerations regarding sirolimus and lung transplantation should be noted (these apply primarily to the United States transplantation procedures):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pretransplant</strong> – Once listed for lung transplant, discontinuation of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> is preferred by many transplant experts due to a potential increased risk of anastomotic dehiscence [<a href="#rid104">104,105</a>], which is included in a boxed warning issued by the FDA.</p><p></p><p class="bulletIndent2">However, this practice, which often leads to rapid deterioration in lung function, has been challenged by some experts since the cases of anastomotic dehiscence that led to the boxed warning occurred when <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> was administered in the postoperative period and at levels higher than those typically used for LAM [<a href="#rid106">106</a>]. Thus, some transplantation experts support the use of low-dose sirolimus in patients on the waitlist based upon the rationale that sirolimus will wash out completely within five to seven days after the drug is discontinued on the day of surgery, three to five weeks before the period when most historic episodes of wound dehiscence occur (at approximately five to six weeks) [<a href="#rid105">105</a>]. <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> has a shorter half-life and washes out in approximately three to four days once the drug is held, leading some experts to recommend a switch to that agent in listed patients. In support of that approach, everolimus has been successfully administered up to the time of transplant in a small number of patients with idiopathic pulmonary fibrosis without occurrence of subsequent bronchial dehiscence [<a href="#rid107">107</a>]. The potential benefits of continuing mTOR inhibitors up until the time of transplantation were also endorsed by the International Society for Heart and Lung Transplantation guidelines [<a href="#rid108">108</a>], and data indicate that &gt;25 percent of transplant centers allow waitlisted patients to remain on mTOR inhibitors [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Posttransplant</strong> – <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> should not be used in the posttransplant period until wound healing is complete (usually at least several months after surgery). When planning antirejection therapies, we recommend that the posttransplant immunosuppressant regimen be optimized for prevention of rejection <strong>without</strong> prioritizing routine use of sirolimus or everolimus for prevention of recurrence. The rationale for this approach is that recurrence of LAM is rare and does not typically threaten graft function [<a href="#rid97">97,98,110</a>] and that mTOR inhibitors are not typically considered first-line antirejection therapies.</p><p></p><p class="bulletIndent2">However, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> has been successfully used for treatment of new onset chylothorax in patients with LAM at three months, and <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> at four weeks, following lung transplant [<a href="#rid111">111</a>]. In some cases, very low-dose sirolimus (eg, 0.5 mg/day) has been added on top of existing immunosuppressive regimens without replacing other agents for chylothorax or evidence of parenchymal recurrence. Several case reports also describe the successful treatment of residual extrapulmonary disease (eg, lymphangioleiomyomas) posttransplant with the use of mTOR inhibitors [<a href="#rid98">98,112,113</a>]. The impact of such therapy on life expectancy and other posttransplant outcomes is unknown.</p><p></p><p class="headingAnchor" id="H1143698034"><span class="h1">INVESTIGATING PROGRESSIVE DYSPNEA</span><span class="headingEndMark"> — </span>The differential diagnosis for progressive shortness of breath in patients with LAM, whether on or off therapy, is broad, and the following etiologies should be considered and treated accordingly. Distinguishing among these entities is usually possible through clinical assessment and appropriate use of pulmonary function testing (PFT), CT of the chest or abdomen, and echocardiography. Etiologies include:</p><p class="bulletIndent1"><span class="glyph">●</span>Progressive pulmonary parenchymal disease due to LAM (see <a class="local">'Treatment of pulmonary LAM'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drug-induced pneumonitis or immunosuppression-related infections due to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> or <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> (see  <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Rapamycin and analogs'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversible airflow obstruction (see  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hypertension (see  <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">"Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">"Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pleuroperitoneal or pericardial chylous effusions (see <a class="local">'Chylothorax and chylous ascites'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary parenchymal lymphatic congestion (see <a class="local">'Other lymphatic disease'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumothorax (see <a class="local">'Pneumothorax'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diaphragmatic impingement by large angiomyolipoma (AML) (see  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary embolism (see  <a class="medical medical_review" href="/z/d/html/8261.html" rel="external">"Clinical presentation, evaluation, and diagnosis of the nonpregnant adult with suspected acute pulmonary embolism"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other non-LAM related etiologies (eg, asthma, heart failure)</p><p></p><p>Lymphatic congestion in the lungs is an ill-defined entity reminiscent of pulmonary edema described in case reports of patients with lymphatic disease [<a href="#rid51">51,56</a>]. It is thought to be caused by reflux of chylous fluid from the axial lymphatics into the pulmonary lymphatics.</p><p class="headingAnchor" id="H1820065254"><span class="h1">TREATMENT OF COMPLICATIONS</span><span class="headingEndMark"> — </span>Sporadic LAM is associated with a number of complications.</p><p class="headingAnchor" id="H3494275254"><span class="h2">Pneumothorax</span><span class="headingEndMark"> — </span>Approximately two-thirds of patients with LAM develop a pneumothorax during the course of their illness [<a href="#rid25">25,114,115</a>]. After the initial pneumothorax, the risk of recurrent ipsilateral, contralateral, or bilateral pneumothorax is high (approximately 70 percent; on average two to four recurrent episodes following the first event). Thus, we and others recommend ipsilateral pleurodesis after the first pneumothorax rather than waiting for a second event [<a href="#rid88">88,114</a>]. (See  <a class="medical medical_review" href="/z/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Pulmonary'</a> and  <a class="medical medical_review" href="/z/d/html/7816.html" rel="external">"Thoracostomy tubes and catheters: Indications and tube selection in adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">"Treatment of secondary spontaneous pneumothorax in adults", section on 'Preventing recurrence and follow-up'</a>.)</p><p>There is no consensus among experts regarding the optimal method of pleurodesis. Options include chemical pleurodesis (eg, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, betadine, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, talc) or surgical pleurodesis (usually via video-assisted thoracoscopy) with mechanical abrasion (partial or complete). Pleurectomy and <a class="drug drug_general" data-topicid="9496" href="/z/d/drug information/9496.html" rel="external">talc pleurodesis</a> are usually reserved for recurrences that follow a prior attempt at pleurodesis. Blebectomy should be avoided at the time of pleurodesis because it may lead to prolonged leak in patients with LAM (presumably because the staple lines involve diseased tissue). Choosing among these options should be individualized and typically varies according to the discretion of the treating pulmonologist and surgeon. Factors that should be taken into consideration include the ability of the patient to tolerate a recurrent pneumothorax or surgery, the presence of a persistent air leak, degree of lung re-expansion, and available expertise. <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> should be held for at least one week prior to and two to four weeks following pleurodesis, to allow for optimal wound healing. We recommend that patients avoid air travel for at least one to two weeks following pleurodesis. Importantly, clinicians should be aware that prior pleurodesis, even bilateral talc pleurodesis, does <strong>not</strong> generally affect candidacy for future lung transplantation at most centers in the United States and Europe [<a href="#rid88">88,114</a>]. (See  <a class="medical medical_review" href="/z/d/html/6695.html" rel="external">"Chemical pleurodesis for the prevention of recurrent pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">"Treatment of secondary spontaneous pneumothorax in adults"</a>.)</p><p>Extrapolating from other populations, <a class="drug drug_general" data-topicid="9496" href="/z/d/drug information/9496.html" rel="external">talc pleurodesis</a> generally results in lowest rates of recurrence. However, we prefer video-assisted thoracoscopic surgery (VATS) guided mechanical abrasion as the initial choice, because it is less likely to cause a degree of pleural fusion that could complicate the removal of the native lung if transplant is required in the future. Talc and pleurectomy are associated with the highest risk of technical complications (eg, bleeding) during future transplantation due to the induction of intense inflammation and pleural symphysis (features that are also responsible for its superior efficacy). However, for those with repeated pneumothoraces or a refractory bronchopleural fistula, talc poudrage may be the most sensible option to avoid protracted attempts to achieve pleural symphysis with less aggressive approaches.</p><p>For unknown reasons, the recurrence rate after pleurodesis is generally higher in LAM than that in other lung diseases (approximately 35 percent versus &lt;5 percent for chronic obstructive pulmonary disease [COPD] and many other lung diseases) and some patients may be left with a residual loculated pneumothorax. One questionnaire-based study of 193 patients with LAM reported recurrence rates of 66 percent after conservative therapy (ie, chest tube drainage), 27 percent after chemical pleurodesis, and 32 percent after surgical pleurodesis [<a href="#rid114">114</a>]. Among those who had undergone transplantation, over one-half had prior pleurodesis with one-third reporting pleural-related postoperative bleeding, albeit without an increase in length of hospital stay or mortality.</p><p>Patient perspectives on the management of pneumothorax may differ from those of clinicians. In a questionnaire-based study of 216 patients with LAM and pneumothorax, most patients felt that pleurodesis was more appropriate for a second rather than a first event [<a href="#rid116">116</a>]. Extensive pain appeared to be a major concern, and most patients felt that clinicians did not fully consider their discomforts or preferences.</p><p>General guidelines for management of pneumothorax from the United States and United Kingdom advise that pleurodesis be performed in those with underlying lung disease who have a first event and in those without underlying lung disease who develop two or more events [<a href="#rid88">88,117,118</a>]. However, the diagnosis of LAM is often not identified until a second or third pneumothorax has been discovered, resulting in a delay in appropriate therapy. We advocate for a low threshold to perform CT of the chest in young (25 to 54 years old), nonsmoking females presenting with a spontaneous pneumothorax (in whom the prevalence of LAM is estimated to be approximately 5 percent) [<a href="#rid119">119,120</a>]. Others estimate a much lower prevalence of LAM in this population and do not recommend CT screening [<a href="#rid121">121</a>].</p><p>Although pneumothoraces definitely occur in LAM patients on <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, several studies have suggested a reduction in the rate of recurrent pneumothoraces with mechanistic target of rapamycin (mTOR) inhibitor therapy [<a href="#rid122">122-124</a>]. However, whether recurrent pneumothoraces constitute an indication to prescribe mTOR inhibitors is not clear.</p><p>Further detailed discussion of the management of pneumothorax is provided separately. (See  <a class="medical medical_review" href="/z/d/html/6695.html" rel="external">"Chemical pleurodesis for the prevention of recurrent pleural effusion"</a> and  <a class="medical medical_review" href="/z/d/html/6706.html" rel="external">"Pneumothorax in adults: Epidemiology and etiology"</a> and  <a class="medical medical_review" href="/z/d/html/6691.html" rel="external">"Treatment of secondary spontaneous pneumothorax in adults"</a> and  <a class="medical medical_review" href="/z/d/html/117242.html" rel="external">"Clinical presentation and diagnosis of pneumothorax", section on 'Diagnostic imaging'</a>.)</p><p class="headingAnchor" id="H2807268613"><span class="h2">Chylothorax and chylous ascites</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> is the initial treatment of choice for symptomatic chylothorax, chylous ascites, lymphangioleiomyomas, and other lymphatic manifestations of LAM (see  <a class="medical medical_review" href="/z/d/html/107651.html" rel="external">"Sporadic lymphangioleiomyomatosis: Clinical presentation and diagnostic evaluation", section on 'Lymphatic manifestations'</a>). This approach is based upon several observational studies that report complete or near-complete resolution of chylous accumulations over months of therapy with sirolimus as well as the lack of consistent benefit from alternative therapies including resection, drainage and pleurodesis, thoracic duct ligation, dietary manipulation, and <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a> [<a href="#rid36">36,48,51,56,113,125-129</a>]. The dose and duration of sirolimus should be similar to that administered for pulmonary disease, although lower doses may also be effective. Importantly, time to resolution varies from 1 to 12 months, so in some instances, a temporary indwelling pleural catheter may be required to drain the pleural space until the full effect of the drug is realized. (See <a class="local">'Sirolimus (first line)'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>In a case series of 12 patients with LAM who had chylous effusions and received off-label <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> for up to 5.4 years (trough level 5 to 15 ng/mL), almost all of the patients experienced complete resolution of their effusion(s) [<a href="#rid51">51</a>]. Adverse effects were similar to those expected with mTOR inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another case series showed that low-dose <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> (trough level, 5 ng/mL or less) was associated with resolution of chylothorax within one to five months in six of seven patients with LAM [<a href="#rid48">48</a>].</p><p></p><p>Dietary modification with a reduced fat, medium chain triglyceride-enriched diet is often recommended for management of chylothorax, but it is often unpalatable, associated with undesirable weight loss, and less likely to be effective when compared with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. We generally do not recommend dietary modifications in patients with chylous accumulations who are being treated with sirolimus. (See  <a class="medical medical_review" href="/z/d/html/16356.html" rel="external">"Management of chylothorax"</a>.)</p><p>Drainage of chylous accumulations in the chest or abdomen is indicated for patients with respiratory compromise (eg, dyspnea, hypoxemia) or abdominal bloating and discomfort. Prolonged drainage (eg, more than two weeks) can result in nutritional depletion and should be limited to patients with significant symptoms from chylous accumulations. Refractory chylous ascites can result when lymphangioleiomyomas are manipulated; consequently, we do not recommend that these lesions be biopsied or resected in most cases.</p><p>In patients with chylous complications that are resistant to <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, the optimal therapy is unknown. We typically obtain lymphatic imaging and refer to a specialized center with expertise in lymphatic disorders [<a href="#rid130">130</a>]. Although evidence is lacking to support one option over another, therapies include a trial of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> and alternative interventions, such as pleuro or peritoneovenous shunts [<a href="#rid131">131,132</a>], pleurodesis, somatostatin analogs or <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>, omental patches [<a href="#rid133">133,134</a>], and thoracic duct manipulation (embolization or ligation). These options are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16356.html" rel="external">"Management of chylothorax"</a>.)</p><p>While <strong>not</strong> generally recommended, anecdotal case reports suggest responses of chylous effusions to hormonal manipulation [<a href="#rid135">135</a>] or fibrin glue for chylous effusions following lung transplant [<a href="#rid136">136</a>]. (See <a class="local">'Statins, doxycycline, hormone manipulation, hydroxychloroquine, celecoxib, resveratrol'</a> below.)</p><p class="headingAnchor" id="H3959814231"><span class="h2">Other lymphatic disease</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with lymphangioleiomyomas</strong> – Biopsy or surgical resection of suspected or known lymphangioleiomyomas and engorged lymph nodes should be avoided due to the risk of prolonged leak, leading to refractory chylous ascites and/or nutrient depletion. <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> appears to be effective for the treatment of even large lymphangioleiomyomas. One case series reported complete resolution of lymphangioleiomyomas in 11 patients treated with sirolimus (mean 2.6 years; trough level 5 to 15 ng/mL) [<a href="#rid51">51</a>] and another showed similar results in three patients treated with lower doses (trough levels 2.9 to 3.5 ng/mL) [<a href="#rid128">128</a>]. Asymptomatic, small lymphangioleiomyomas do not generally constitute an independent indication for sirolimus treatment.</p><p></p><p class="bulletIndent1">Similar results have been reported with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>. Everolimus was administered in an open-label study to five patients with lymphangioleiomyomas complicating LAM [<a href="#rid137">137</a>]. All five experienced substantial shrinkage or complete resolution of the lymphangioleiomyomas. However, cessation of everolimus resulted in a recurrence in one patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with lymphadenopathy</strong> – Lymphadenopathy generally resolves or improves in patients with LAM who are treated with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> for pulmonary disease, although there is a paucity of data supporting this observation and it is rare that lymphadenopathy would be an indication for treatment per se.</p><p></p><p class="headingAnchor" id="H2526277925"><span class="h2">Angiomyolipomas</span><span class="headingEndMark"> — </span>Most renal angiomyolipomas (AMLs) in patients with sporadic LAM do not require therapy since most are unilateral, solitary, and quiescent; hemorrhage and renal compromise are rare. For large (&gt;4 cm), symptomatic or growing AMLs &gt;3 cm, treatment strategies should be similar to those in patients with tuberous sclerosis complex (TSC) [<a href="#rid138">138</a>]. mTOR inhibitor therapy is now the first line approach and is approved for treatment of AMLs in patients with TSC. Embolization, radiofrequency ablation, or nephron-sparing partial nephrectomy are considered for tumors that fail to adequately shrink on mTOR inhibitor therapy or those that are at very high risk of bleeding [<a href="#rid138">138</a>]. Nephron sparing approaches are preferred, and nephrectomy should only be considered as a last resort or when renal cancer is documented or strongly suspected. Further details are provided separately. (See  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>.)</p><p>Hepatic AMLs generally do not require specific treatment [<a href="#rid139">139-141</a>].</p><p class="headingAnchor" id="H3075689083"><span class="h2">COVID-19</span><span class="headingEndMark"> — </span>Individuals with LAM who have coronavirus disease 2019 (COVID-19) should be managed similarly to other patients with chronic lung disease. (See  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p>Notably, <a class="drug drug_general" data-topicid="134695" href="/z/d/drug information/134695.html" rel="external">nirmatrelvir-ritonavir</a> can raise the <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> blood levels. We ask LAM patients to either hold sirolimus or take sirolimus on alternate days (eg, patients with severe disease) for the duration of treatment (five days).</p><p>In a retrospective study, the risk of death after COVID-19 infection in women with LAM was found to be similar to the general population and the use of mTOR inhibitors was not associated with worse outcomes. This study included 91 patients with LAM (mostly sporadic LAM), with 31 percent requiring hospital admission, 2.2 percent requiring noninvasive ventilation, and 2.2 percent requiring mechanical ventilation [<a href="#rid142">142</a>]. Only one patient died, a 59 year old with severe lung disease. Diffusing capacity, but not mTOR inhibitor therapy, was predictive of the need for hospitalization or supplemental oxygen (odds ratio 0.96, 95% CI 0.93-0.99). The young age of this population may explain the favorable outcomes compared with other chronic lung disease cohorts.</p><p class="headingAnchor" id="H3626018072"><span class="h2">Others</span><span class="headingEndMark"> — </span>Other complications of LAM should be managed similarly to the general population:</p><p class="bulletIndent1"><span class="glyph">●</span>Meningiomas (see  <a class="medical medical_review" href="/z/d/html/5230.html" rel="external">"Management of known or presumed benign (WHO grade 1) meningioma"</a> and  <a class="medical medical_review" href="/z/d/html/15692.html" rel="external">"Management of atypical and malignant (WHO grade 2 and 3) meningioma"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Osteoporosis (see  <a class="medical medical_review" href="/z/d/html/2064.html" rel="external">"Overview of the management of low bone mass and osteoporosis in postmenopausal women"</a> and  <a class="medical medical_review" href="/z/d/html/2060.html" rel="external">"Evaluation and treatment of premenopausal osteoporosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hypertension [<a href="#rid143">143,144</a>] (see  <a class="medical medical_review" href="/z/d/html/8258.html" rel="external">"Pulmonary hypertension due to lung disease and/or hypoxemia (group 3 pulmonary hypertension): Treatment and prognosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary vascular shunts [<a href="#rid145">145</a>] (see  <a class="medical medical_review" href="/z/d/html/16891.html" rel="external">"Therapeutic approach to adult patients with pulmonary arteriovenous malformations"</a>)</p><p></p><p class="headingAnchor" id="H3762237998"><span class="h1">THERAPY OF UNCLEAR BENEFIT</span></p><p class="headingAnchor" id="H1045408431"><span class="h2">Statins, doxycycline, hormone manipulation, hydroxychloroquine, celecoxib, resveratrol</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – Statins have potential noncardiovascular benefits, including preclinical evidence suggesting potential for inducing LAM cell death when used in combination with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. A retrospective review of combined sirolimus and <a class="drug drug_general" data-topicid="9923" href="/z/d/drug information/9923.html" rel="external">simvastatin</a> therapy showed that the addition of a statin neither enhances nor diminishes the beneficial effects of sirolimus therapy in LAM [<a href="#rid146">146</a>]. A phase II open-label clinical trial where simvastatin was administered in escalating doses to 10 patients with LAM on a stable dose of sirolimus showed that while the combination of simvastatin and sirolimus was safe, there was a trend towards increased FEV<sub>1</sub> decline with this combination [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">Doxycycline</a> – Doxycycline, a matrix metalloproteinase inhibitor, has been tested as a possible treatment for pulmonary LAM [<a href="#rid84">84,147-150</a>]. Although there is a paucity of data, most studies suggest no benefit. In a trial of 23 women with pulmonary LAM who were randomly assigned to take oral doxycycline 100 mg daily for three months followed by 200 mg daily for 21 months, or matched placebo [<a href="#rid84">84</a>], there was no indication that doxycycline had an effect on mean decline in forced expiratory volume in one second (FEV<sub>1</sub>), vital capacity, gas transfer, shuttle walk distance, or quality of life. Unfortunately, only 15 subjects completed two years of treatment, and the study was inadequately powered for definitive conclusions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hormone manipulation</strong> – Historically, hormonal manipulation has been used to treat LAM, based upon the presumption that estrogen likely plays a role in the pathogenesis of the disease. However, anti-estrogen approaches are not currently recommended for routine use because pivotal trials have not been done and consistent benefit has not been demonstrated [<a href="#rid2">2</a>]. Large randomized trials will be required to identify subpopulations that may benefit (eg, premenopausal patients with pneumothorax, menstrual cycle variation, or lymphatic involvement).</p><p></p><p class="bulletIndent1">Consistent with American Thoracic Society/Japanese Respiratory Society (ATS/JRS) LAM Guidelines, hormone manipulation should not be used for routine treatment of LAM [<a href="#rid2">2</a>]. This recommendation is based upon lack of convincing evidence for efficacy of various hormonal manipulations, including progestin therapy (high dose <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> given as intramuscular depot injection or orally), <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a> (20 mg/day), oophorectomy, androgen therapy, luteinizing hormone-releasing hormone (LHRH) analogs, aromatase inhibitors, and combinations of such therapies [<a href="#rid1">1,82,151-159</a>]. No trial has shown convincing benefits and many experts believe that the potential harms from undesirable adverse effects (eg, osteoporosis, accelerated cardiovascular disease, mood swings, hirsutism, weight gain, venous thromboembolism) preclude recommending them for routine use.</p><p></p><p class="bulletIndent1">For patients with progressive disease who do not respond to a mechanistic target of rapamycin (mTOR) inhibitor (eg, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>), enrollment in a clinical trial may be offered or a limited trial of estrogen suppression with gonadotropin-releasing hormone (GnRH) agonists (eg, Lupron) plus or minus aromatase inhibitor therapy may be given, depending on menopausal status [<a href="#rid1">1</a>]. The rationale for this approach is strongest in premenopausal patients, especially in those who have symptoms or disease manifestations that vary with the menstrual cycle [<a href="#rid160">160</a>], but strong evidence to support this practice is lacking.</p><p></p><p class="bulletIndent1">For those who require hormonal manipulation for <strong>non-LAM</strong> indications (eg, breast cancer, contraception, dysmenorrhea, catamenial pneumothorax), estrogen-containing medications should be avoided including selective estrogen response modulators with estrogen agonist properties such as <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">tamoxifen</a>. Use of aromatase inhibitors, progestins, or low dose estrogen or progestin-eluting intravaginal or intrauterine devices (IUDs) are not contraindicated. Selecting a method of contraception is discussed separately. (See <a class="local">'Pregnancy and birth control'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8541" href="/z/d/drug information/8541.html" rel="external">Hydroxychloroquine</a> – Autophagy inhibition has been proposed as a mechanism to induce LAM cell death. Hydroxychloroquine is a potent inhibitor of autophagy and based on promising preclinical evidence was the subject of investigation in a phase I trial in LAM [<a href="#rid83">83</a>]. In this study, 13 LAM patients received hydroxychloroquine in an escalating dose manner along with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> for 24 weeks followed by 24 weeks of observation off treatment. Five subjects withdrew early due to FEV<sub>1</sub> decline or adverse effects. Although there was a slight trend towards improved lung function with the combination, the study was not powered to determine efficacy. The role of hydroxychloroquine in the treatment of LAM remains undefined and warrants further investigation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8847" href="/z/d/drug information/8847.html" rel="external">Celecoxib</a> – Celecoxib, a selective COX-2 inhibitor, was studied in a phase I open-label trial in 12 patients with LAM not on <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>. Celecoxib 200 mg was given daily for 24 weeks. Three participants withdrew due to adverse effects. While the study demonstrated the overall safety of using celecoxib in LAM, larger trials are needed to demonstrate the efficacy of this approach [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resveratrol</strong> – The safety and efficacy of combined resveratrol and <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> was assessed in a phase 2 open-label clinical trial involving 25 patients with LAM [<a href="#rid87">87</a>]. Resveratrol was started at a dose of 250 mg daily and titrated to a maximum dose of 500 mg twice daily. The addition of resveratrol was safe and well tolerated and was associated with modest reduction in serum VEGF-D levels and improvement in health-related quality of life. Larger placebo controlled trials are needed to definitively assess the efficacy of resveratrol in LAM.</p><p></p><p class="headingAnchor" id="H3395216646"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H71235619"><span class="h2">Lung function decline (off therapy)</span><span class="headingEndMark"> — </span>Based upon early observational data from national registries and referral centers, the annual decline in forced expiratory volume in one second (FEV<sub>1</sub>) in untreated LAM patients has been reported to range from 40 to 120 mL/year and higher [<a href="#rid157">157,158,161-163</a>]. Rapid deterioration in lung function can occur at the outset or during the course of the disease [<a href="#rid154">154,158,164</a>]. As an example, in randomized studies of <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> and <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, the annual decline in the placebo groups was 90 and 134 mL/year, respectively; although, these studies excluded patients with normal or mildly impaired lung function [<a href="#rid47">47,84</a>]. An analysis of the National Heart, Lung, and Blood Institute's (NHLBI) LAM Registry has demonstrated an annual rate of decline in FEV<sub>1</sub> of 89 mL/year, with a faster rate of decline in patients with higher cyst profusion on chest CT scans and in premenopausal as compared with postmenopausal women [<a href="#rid163">163</a>]. The effect of sirolimus on lung function is described separately. (See <a class="local">'Sirolimus (first line)'</a> above.)</p><p class="headingAnchor" id="H2926446873"><span class="h2">Mortality</span><span class="headingEndMark"> — </span>While early retrospective studies reported that the median survival for patients with LAM was 8 to 10 years from diagnosis [<a href="#rid164">164,165</a>], data now suggest that survival is longer than previously thought [<a href="#rid157">157,166-171</a>]; these differences likely reflect biases introduced by different modes of data ascertainment (hospital based versus population based cohorts) rather than a true improvement in survival.</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based registry of 1149 self-identified LAM patients, the estimated median transplant-free survival time in the United States is 29 years from symptom onset and 23 years from diagnosis [<a href="#rid166">166</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another study that used data derived from a United Kingdom database reported 10-year survival was 91 percent from onset of symptoms. A wide variation in survival was reported, but 20 percent of the cohort remained alive after 20 years [<a href="#rid168">168</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the NHLBI longitudinal LAM registry, the estimated 5-, 10-, 15-, and 20-year transplant-free survival rates were 95, 85, 75, and 64 percent, respectively [<a href="#rid163">163</a>].</p><p></p><p><a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> may also reduce the time to transplant. A four-year prospective observational study reported that the decline in FEV<sub>1</sub> for patients with LAM was slower than previously reported, which may reflect improved therapies for this disease in the sirolimus era [<a href="#rid167">167</a>]. One retrospective study reported an eight-year cumulative survival rate of 90 percent in patients treated with sirolimus compared with 78 percent in those not taking sirolimus despite worse baseline lung function and symptoms in the sirolimus treatment group (eg, FEV<sub>1</sub> 64 versus 86 percent) [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H4145222409"><span class="h2">Prognostic factors</span><span class="headingEndMark"> — </span>While many prognostic factors have been proposed, none have been validated prospectively. These include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Premenopausal status</strong> – Longitudinal studies, case series, and randomized trial data report that premenopausal women tend to have a faster rate of decline in lung function than postmenopausal women [<a href="#rid47">47,154,158,163</a>]. As an example, the NHLBI Longitudinal Study reported that the rate of FEV<sub>1</sub> decline was greater in premenopausal subjects (118 mL/year) compared with postmenopausal subjects (74mL/year) and that premenopausal status at baseline was associated with higher rates of death or need for transplant. This finding was supported by a post-hoc analysis of the MILES trial in which premenopausal women with LAM had a FEV<sub>1</sub> decline rate that was roughly fivefold higher than the postmenopausal women (approximately 200 mL/year versus approximately 40 mL/year) [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Presentation with dyspnea</strong> – Some case series report that presentation with dyspnea on exertion, as opposed to pneumothorax, is associated with a worse prognosis [<a href="#rid115">115,166</a>]. This is intuitively plausible, because a sentinel pneumothorax may reveal LAM in early stages, while dyspnea on exertion at presentation is likely associated with a significant disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sporadic variant</strong> – It is generally thought that women with tuberous sclerosis complex (TSC) have milder lung impairment and a more indolent course than those with sporadic LAM [<a href="#rid25">25</a>]. However, when patients with TSC and sporadic variants with similar degrees of lung function impairment are compared, there is no difference in the rate of lung function decline [<a href="#rid172">172</a>]. The NHLBI Longitudinal Study reported that LAM subtype (TSC-LAM versus sporadic LAM) at baseline was not associated with a poor outcome (death or transplant). Ascertainment bias likely plays a significant role in the perception that TSC-LAM is milder than sporadic LAM since the ability to screen a susceptible TSC population more readily identifies disease at early stages. (See  <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">"Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hormonal manipulation</strong> – Treatment with hormonal therapy, in particular <a class="drug drug_general" data-topicid="9817" href="/z/d/drug information/9817.html" rel="external">progesterone</a>, was found in one retrospective study to be associated with an increased risk of death [<a href="#rid166">166</a>]. In another retrospective study, progesterone therapy was found to be associated with an accelerated rate of decline in diffusing capacity for carbon monoxide (DLCO) [<a href="#rid154">154</a>]. In both cases, interpretation was likely confounded by indication, since the group of patients on progesterone was likely more severely affected; prompting the intervention.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung function</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Poor baseline lung function</strong> – Several studies report that abnormal pulmonary function on presentation (eg, reduced FEV<sub>1</sub> ≤70 percent predicted, elevated total lung capacity [TLC] and a reduced FEV<sub>1</sub>/forced vital capacity [FVC] ratio) were negative prognostic indicators [<a href="#rid154">154,162,165</a>]. Abnormal gas exchange requiring oxygen supplementation was found to be associated with poor outcome in another study [<a href="#rid166">166</a>] (see  <a class="medical medical_review" href="/z/d/html/4329.html" rel="external">"Tuberous sclerosis complex associated lymphangioleiomyomatosis in adults"</a>). The NHLBI LAM Registry Longitudinal Study reported that better baseline lung function (FEV<sub>1</sub>) was associated with better outcome (eg, death or transplant) [<a href="#rid163">163</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reversible airflow obstruction</strong> – Observational studies report that reversible airflow obstruction may be a predictor of worse disease severity and disease progression [<a href="#rid7">7,173</a>]. However, airflow obstruction at baseline did not have an impact on outcome (eg, death or transplant) in the NHLBI LAM Registry Longitudinal Study [<a href="#rid163">163</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Historical rate of lung function decline</strong> – Several studies suggest that the best predictor of the future rate of lung function decline is the historical rate of lung function decline. (See <a class="local">'Monitored observation'</a> above and <a class="local">'Lung function decline (off therapy)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiologic findings</strong> – Several radiologic and pathologic studies report that predominance of cystic lung disease, rather than ground glass or nodular opacities, is associated with a worse prognosis [<a href="#rid7">7,165,171</a>]. It is unknown whether these patterns represent two distinct histopathologic categories of disease or different stages in disease evolution [<a href="#rid165">165</a>]. A close correlation has also been noted between the extent of the cystic parenchymal changes (as measured by quantitative CT) and disease severity (as determined by spirometry, diffusing capacity, lung volumes, or exercise performance) and rate of decline of lung function [<a href="#rid163">163,174-176</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High levels of serum vascular endothelial growth factor-D (VEGF-D)</strong> – High VEGF-D levels correlate with oxygen supplementation, bronchodilator response, and disease severity in LAM [<a href="#rid43">43</a>], yet the prognostic value of VEGF-D remains uncertain. One observational study involving patients receiving <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> showed increased survival in those with baseline VEGF-D of &lt;2000 pg/mL compared with VEGF-D of ≥2000 pg/mL (95 versus 83 percent) [<a href="#rid60">60</a>]. In a separate observational study of LAM patients not on sirolimus, those with serum VEGF-D level ≥800 pg/mL had a significantly greater lung function decline compared with patients with a VEGF-D level &lt;800 pg/mL [<a href="#rid44">44</a>]. However, baseline VEGF-D levels were not predictive of future progression to death or lung transplantation in the NHLBI LAM Registry Longitudinal Study and a separate longitudinal natural history study in Japan [<a href="#rid75">75,163</a>].</p><p></p><p class="bulletIndent1">Treatment response has also been linked to VEGF-D levels. In a post-hoc analysis of a randomized trial of <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, patients who experienced more than a 42 percent reduction in VEGF-D levels were more likely to exhibit a positive lung function response compared with those whose VEGF-D levels did not respond (&lt;42 percent reduction) [<a href="#rid43">43,45</a>]. VEGF-D responders were also more likely to have elevated baseline VEGF-D levels, possibly due to the use of a percent reduction to define VEGF-D response.</p><p></p><p>Conversely, it is generally believed that good prognostic features include older age, postmenopausal status, initial presentation with pneumothorax, and normal or mild dysfunction on pulmonary function tests.</p><p class="headingAnchor" id="H1383681417"><span class="h1">ADDITIONAL RESOURCES</span><span class="headingEndMark"> — </span>The LAM Foundation endorses LAM specialty clinics across the United States and around the world; a list of these clinics, international LAM patient advocacy groups, and other useful information can be found at these sites: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thelamfoundation.org%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUrxDyepJycAgsqoy5dhzs0bCF1D5kRrCZy7y52FO2E76b&amp;TOPIC_ID=107652" target="_blank">The LAM Foundation</a>, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tscalliance.org%2F&amp;token=mvT%2Ffm0DU2zopq8%2B0NghZ2CdwZjgJMb445bhsxSGUNrB%2B5rZUKGMV%2BWX3duc5h8T&amp;TOPIC_ID=107652" target="_blank">Tuberous Sclerosis Alliance</a>, and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fuc.cloud-cme.com%2FDefault.aspx%3Fp%3D13%26eid%3D20754&amp;token=2RVgbeNLg4omtUDummKzEXUa4TNmK2COOwfeldphwB8PDfvnOn%2BgB9fk80GMCVy7akTqwRpyww8WOgG22xqi8w%3D%3D&amp;TOPIC_ID=107652" target="_blank">University of Cincinnati</a>.</p><p class="headingAnchor" id="H2124725159"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118842.html" rel="external">"Society guideline links: Lymphangioleiomyomatosis"</a>.)</p><p class="headingAnchor" id="H4089942997"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/117229.html" rel="external">"Patient education: Lymphangioleiomyomatosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2068148413"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/131727.html" rel="external">"Patient perspective: Lymphangioleiomyomatosis (LAM)"</a>.)</p><p class="headingAnchor" id="H1431933454"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology</strong> – Lymphangioleiomyomatosis (LAM) is a rare multisystem disorder that mostly afflicts women and primarily affects the lung. The term sporadic LAM is used for patients with pulmonary LAM who do not have tuberous sclerosis complex. (See  <a class="medical medical_review" href="/z/d/html/4335.html" rel="external">"Sporadic lymphangioleiomyomatosis: Epidemiology and pathogenesis", section on 'Introduction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – General measures used to treat LAM include reassurance, use of supplemental oxygen, bronchodilators, pulmonary rehabilitation, interventions to manage complications, and avoidance of estrogen-containing medications. The strategic use of the mechanistic target of rapamycin (mTOR) inhibitor, <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, slows progression of respiratory impairment but is not curative. Early referral to or consultation with a LAM center is prudent to establish shared care between LAM experts and local pulmonologists. (See <a class="local">'General measures'</a> above and <a class="local">'Treatment of complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of lung disease</strong> – Our approach is the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal or mildly impaired lung function</strong> – For most patients with LAM who have normal or mildly impaired lung function defined as a forced expiratory volume in one second (FEV<sub>1</sub>) ≥70 percent, we suggest monitored observation with frequent postbronchodilator lung function assessments at three month intervals rather than treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Sirolimus may be appropriate in patients with FEV<sub>1</sub> in the normal range if lung function is rapidly declining (eg, &gt;100 mL/year) or there are other lung function abnormalities suggestive of a significant burden of LAM in the lung, such as evidence of air trapping (residual volume &gt;120 percent), heavy burden of cysts, abnormal diffusion capacity for carbon monoxide (&lt;lower limit of normal), or &gt;4 percent oxygen desaturation with ambulation. (See <a class="local">'Normal or mildly impaired lung function'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Moderate to severe lung impairment</strong> – For most patients with sporadic LAM who have moderate to severe lung impairment, as defined by an FEV<sub>1</sub> &lt;70 percent predicted, we recommend treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> rather than observation (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). In select patients, a short period of observation may be prudent to assess disease progression before initiating sirolimus (eg, postmenopausal women with good pulmonary reserve, given slower rate of progression in that subgroup). Sirolimus is typically administered at 1 to 2 mg orally per day and adjusted to levels required to stabilize lung function and minimize adverse effects ensuring that the trough level does not exceed 10 ng/mL. While the optimal duration of therapy is unknown, we generally continue sirolimus indefinitely, as tolerated. <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">Everolimus</a> is an alternative mTOR inhibitor for those who do not tolerate or respond to sirolimus. (See <a class="local">'Moderate to severe lung function impairment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory disease</strong> – For patients who have progressive lung disease despite <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a>, options include increasing the dose of sirolimus toward the upper end of the therapeutic range (ie, 10 to 15 ng/mL), a trial of replacement with <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a>, participation in clinical trials, and referral for lung transplantation. Although <strong>not</strong> routinely recommended, hormonal manipulation is sometimes administered in this population. Choosing among these options is dependent upon factors including menopausal status, presence of menstrual cycle associated variation in respiratory symptoms, patient preference and pulmonary reserve. (See <a class="local">'Refractory disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of complications</strong> – Our approach to complications is the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pneumothorax</strong> – For most patients with LAM and a pneumothorax, after chest tube drainage, we recommend ipsilateral pleurodesis at the time of the initial pneumothorax, rather than waiting for a recurrent event (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>). We favor mechanical pleurodesis via a video-assisted thoracoscopy and reserve <a class="drug drug_general" data-topicid="9496" href="/z/d/drug information/9496.html" rel="external">talc pleurodesis</a> for those who fail this approach. <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">Sirolimus</a> should be held in the perioperative period. (See <a class="local">'Pneumothorax'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chylous disease</strong> <strong>and lymphangioleiomyomas</strong> – For most patients with symptomatic chylous accumulations or lymphangioleiomyomas, we suggest treatment with <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> rather than other therapies or invasive procedures (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Chylothorax and chylous ascites'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Angiomyolipomas</strong> – Many renal angiomyolipomas (AMLs) in patients with sporadic LAM do not require therapy since most are unilateral, solitary, and quiescent; hemorrhage and renal compromise are rare. Indications for treatment are described separately. (See <a class="local">'Angiomyolipomas'</a> above and  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational agents</strong> – Several other agents are under investigation (eg, statins, resveratrol; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3Dlymphangioleiomyomatosis&amp;token=JKcSmCXgdKvw9eDYrJDw9oeiz6hQPhqvolXEeStyEFMZoxMS8ktK%2BcvVvauZctRupS1MrSHzJrGBnTLLytyNM7qFY66gUuI%2FTQNKdcgyoB4%3D&amp;TOPIC_ID=107652" target="_blank">Clinicaltrials.gov</a>) or have been studied in the past and found to be of no or unclear benefit (eg, <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>). Hormonal manipulation has not been shown to be effective for treatment of LAM and should <strong>not</strong> be used routinely to treat LAM. (See <a class="local">'Clinical trials'</a> above and <a class="local">'Therapy of unclear benefit'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – The estimated median transplant-free survival time for pulmonary LAM is 29 years from symptom onset and 23 years from diagnosis. Factors associated with poor prognosis are often those that are associated with faster rates of decline in lung function. Newer data suggests that <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">sirolimus</a> reduces mortality and time to transplant. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Educational information</strong> – Important educational information is provided at the following sites: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thelamfoundation.org%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUrxDyepJycAgsqoy5dhzs0bCF1D5kRrCZy7y52FO2E76b&amp;TOPIC_ID=107652" target="_blank">The LAM Foundation</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.tscalliance.org%2F&amp;token=mvT%2Ffm0DU2zopq8%2B0NghZ2CdwZjgJMb445bhsxSGUNrB%2B5rZUKGMV%2BWX3duc5h8T&amp;TOPIC_ID=107652" target="_blank">Tuberous Sclerosis Alliance</a>. (See <a class="local">'Additional resources'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35:14.</a></li><li><a class="nounderline abstract_t">McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med 2016; 194:748.</a></li><li><a class="nounderline abstract_t">Medeiros P Jr, Lorenzi-Filho G, Pimenta SP, et al. Sleep desaturation and its relationship to lung function, exercise and quality of life in LAM. Respir Med 2012; 106:420.</a></li><li><a class="nounderline abstract_t">Bahmer T, Watz H, Waschki B, et al. Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates. Thorax 2016; 71:662.</a></li><li><a class="nounderline abstract_t">Araujo MS, Baldi BG, Freitas CS, et al. Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial. Eur Respir J 2016; 47:1452.</a></li><li><a class="nounderline abstract_t">Fritz H, Seely D, Flower G, et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS One 2013; 8:e81968.</a></li><li><a class="nounderline abstract_t">Taveira-DaSilva AM, Hedin C, Stylianou MP, et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2001; 164:1072.</a></li><li><a class="nounderline abstract_t">Burger CD. Variability in the prevalence of acute bronchoresponsiveness in different populations of patients with lymphangioleiomyomatosis. Chest 2008; 134:217; author reply 218.</a></li><li><a class="nounderline abstract_t">Baldi BG, de Albuquerque AL, Pimenta SP, et al. A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM. Respir Med 2013; 107:1773.</a></li><li><a class="nounderline abstract_t">Taveira-DaSilva AM, Burstein D, Hathaway OM, et al. Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis. Chest 2009; 136:665.</a></li><li><a class="nounderline abstract_t">Pollock-BarZiv S, Cohen MM, Downey GP, et al. Air travel in women with lymphangioleiomyomatosis. Thorax 2007; 62:176.</a></li><li><a class="nounderline abstract_t">Gonano C, Pasquier J, Daccord C, et al. Air travel and incidence of pneumothorax in lymphangioleiomyomatosis. Orphanet J Rare Dis 2018; 13:222.</a></li><li><a class="nounderline abstract_t">Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer: Clinical Consensus. Obstet Gynecol 2021; 138:950.</a></li><li><a class="nounderline abstract_t">Johnson SR, Tattersfield AE. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55:1052.</a></li><li><a class="nounderline abstract_t">Cleary-Goldman J, Sanghvi AV, Nakhuda GS, Robinson JN. Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy. J Matern Fetal Neonatal Med 2004; 15:132.</a></li><li><a class="nounderline abstract_t">Brunelli A, Catalini G, Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynaecol Obstet 1996; 52:289.</a></li><li><a class="nounderline abstract_t">Mitra S, Ghosal AG, Bhattacharya P. Pregnancy unmasking lymphangioleiomyomatosis. J Assoc Physicians India 2004; 52:828.</a></li><li><a class="nounderline abstract_t">Fujimoto M, Ohara N, Sasaki H, et al. Pregnancy complicated with pulmonary lymphangioleiomyomatosis: case report. Clin Exp Obstet Gynecol 2005; 32:199.</a></li><li><a class="nounderline abstract_t">McLoughlin L, Thomas G, Hasan K. Pregnancy and lymphangioleiomyomatosis: anaesthetic management. Int J Obstet Anesth 2003; 12:40.</a></li><li><a class="nounderline abstract_t">Cohen MM, Freyer AM, Johnson SR. Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med 2009; 103:766.</a></li><li><a class="nounderline abstract_t">Raft J, Lalot JM, Meistelman C, Longrois D. [Renal angiomyolipoma rupture during pregnancy]. Gynecol Obstet Fertil 2006; 34:917.</a></li><li><a class="nounderline abstract_t">Storm DW, Mowad JJ. Conservative management of a bleeding renal angiomyolipoma in pregnancy. Obstet Gynecol 2006; 107:490.</a></li><li><a class="nounderline abstract_t">Morales JP, Georganas M, Khan MS, et al. Embolization of a bleeding renal angiomyolipoma in pregnancy: case report and review. Cardiovasc Intervent Radiol 2005; 28:265.</a></li><li><a class="nounderline abstract_t">Munshi A, Hyslop AD, Kopras EJ, Gupta N. Spontaneous pneumothoraces during pregnancy in patients with lymphangioleiomyomatosis. Respir Investig 2023; 61:632.</a></li><li><a class="nounderline abstract_t">Ryu JH, Moss J, Beck GJ, et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173:105.</a></li><li><a class="nounderline abstract_t">Taveira-DaSilva AM, Johnson SR, Julien-Williams P, et al. Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts. Thorax 2020; 75:904.</a></li><li><a class="nounderline abstract_t">Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 2002; 57:1085.</a></li><li><a class="nounderline abstract_t">Shen A, Iseman MD, Waldron JA, King TE. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest 1987; 91:782.</a></li><li><a class="nounderline abstract_t">Wilson AM, Slack HL, Soosay SA, et al. Lymphangioleiomyomatosis. A series of three case reports illustrating the link with high oestrogen states. Scott Med J 2001; 46:150.</a></li><li><a class="nounderline abstract_t">Oberstein EM, Fleming LE, Gómez-Marin O, Glassberg MK. Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease. J Womens Health (Larchmt) 2003; 12:81.</a></li><li><a class="nounderline abstract_t">Faehling M, Wienhausen-Wilke V, Fallscheer S, et al. Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM). Sarcoidosis Vasc Diffuse Lung Dis 2015; 32:259.</a></li><li><a class="nounderline abstract_t">Faehling M, Frohnmayer S, Leschke M, et al. Successful pregnancy complicated by persistent pneumothorax in a patient with lymphangioleiomyomatosis (LAM) on sirolimus. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28:153.</a></li><li><a class="nounderline abstract_t">Jankowska I, Oldakowska-Jedynak U, Jabiry-Zieniewicz Z, et al. Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient. Transplant Proc 2004; 36:3232.</a></li><li><a class="nounderline abstract_t">Cai X, Pacheco-Rodriguez G, Haughey M, et al. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis. Chest 2014; 145:108.</a></li><li><a class="nounderline abstract_t">Cai X, Pacheco-Rodriguez G, Fan QY, et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med 2010; 182:1410.</a></li><li><a class="nounderline abstract_t">Harari S, Elia D, Torre O, et al. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells. Chest 2016; 150:e29.</a></li><li><a class="nounderline abstract_t">Eder AF, Ryu JH, Moss J. Should lymphangioleiomyomatosis patients be permitted to donate blood? Eur Respir J 2016; 47:1883.</a></li><li><a class="nounderline abstract_t">Cottin V, Blanchard E, Kerjouan M, et al. French recommendations for the diagnosis and management of lymphangioleiomyomatosis. Respir Med Res 2023; 83:101010.</a></li><li><a class="nounderline abstract_t">Johnson J, Stewart I, Johnson SR. Disease monitoring using lung function trajectory in lymphangioleiomyomatosis: assessment in two national cohorts. Thorax 2023; 78:61.</a></li><li><a class="nounderline abstract_t">Palipana AK, Gecili E, Song S, et al. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis. Chest 2023; 163:1458.</a></li><li><a class="nounderline abstract_t">National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395.</a></li><li><a class="nounderline abstract_t">Hu-Wang E, Schuzer JL, Rollison S, et al. Chest CT Scan at Radiation Dose of a Posteroanterior and Lateral Chest Radiograph Series: A Proof of Principle in Lymphangioleiomyomatosis. Chest 2019; 155:528.</a></li><li><a class="nounderline abstract_t">Young L, Lee HS, Inoue Y, et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 2013; 1:445.</a></li><li><a class="nounderline abstract_t">Radzikowska E, Jaguś P, Sobiecka M, et al. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis. Respir Med 2015; 109:1469.</a></li><li><a class="nounderline abstract_t">Gupta N, Lee HS, Young LR, et al. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. Eur Respir J 2019; 53.</a></li><li class="breakAll">U.S. Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448523.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery#.VWeLfP4WDY8.facebook (Accessed on May 29, 2015).</li><li><a class="nounderline abstract_t">McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364:1595.</a></li><li><a class="nounderline abstract_t">Ando K, Kurihara M, Kataoka H, et al. Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis. Respir Investig 2013; 51:175.</a></li><li><a class="nounderline abstract_t">Bhorade S, Ahya VN, Baz MA, et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med 2011; 183:379.</a></li><li><a class="nounderline abstract_t">Shitrit D, Rahamimov R, Gidon S, et al. Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study. Kidney Int 2005; 67:1471.</a></li><li><a class="nounderline abstract_t">Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154:797.</a></li><li><a class="nounderline abstract_t">Yao J, Taveira-DaSilva AM, Jones AM, et al. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med 2014; 190:1273.</a></li><li><a class="nounderline abstract_t">McCormack FX. Chronic sirolimus therapy for lymphangioleiomyomatosis. Am J Respir Crit Care Med 2014; 190:1332.</a></li><li><a class="nounderline abstract_t">Takada T, Mikami A, Kitamura N, et al. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis. Ann Am Thorac Soc 2016; 13:1912.</a></li><li><a class="nounderline abstract_t">Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358:140.</a></li><li><a class="nounderline abstract_t">Moua T, Olson EJ, Jean HC, Ryu JH. Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med 2012; 186:389.</a></li><li><a class="nounderline abstract_t">Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008; 358:200.</a></li><li><a class="nounderline abstract_t">Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS One 2011; 6:e23379.</a></li><li><a class="nounderline abstract_t">Bee J, Fuller S, Miller S, Johnson SR. Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. Thorax 2018; 73:369.</a></li><li><a class="nounderline abstract_t">Xu W, Yang C, Cheng C, et al. Determinants of Progression and Mortality in Lymphangioleiomyomatosis. Chest 2023; 164:137.</a></li><li><a class="nounderline abstract_t">Montero MA, Roman A, Berastegui C. Radical reduction of smooth muscle cells in explanted lung of a LAM patient treated with sirolimus: first case report. J Heart Lung Transplant 2012; 31:439.</a></li><li><a class="nounderline abstract_t">Neurohr C, Hoffmann AL, Huppmann P, et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis? Respir Res 2011; 12:66.</a></li><li><a class="nounderline abstract_t">de Oliveira MA, Martins E Martins F, Wang Q, et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011; 47:998.</a></li><li><a class="nounderline abstract_t">Boers-Doets CB, Raber-Durlacher JE, Treister NS, et al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol 2013; 9:1883.</a></li><li><a class="nounderline abstract_t">Singla A, Gupta N, Apewokin S, McCormack F. Sirolimus for the treatment of lymphangioleiomyomatosis. Expert Opinion on Orphan Drugs 2017; 5:907.</a></li><li><a class="nounderline abstract_t">Subramaniam S, Zell JA, Kunz PL. Everolimus causing severe hypertriglyceridemia and acute pancreatitis. J Natl Compr Canc Netw 2013; 11:5.</a></li><li><a class="nounderline abstract_t">Courtwright AM, Goldberg HJ, Henske EP, El-Chemaly S. The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis. Eur Respir Rev 2017; 26.</a></li><li class="breakAll">Mannick JB, Morris M, Hockey HP, et al. TORC1 inhibition enhances immune function and reduces infections in the elderly. Science Translational Medicine 2018; 10. http://stm.sciencemag.org/content/10/449/eaaq1564 (Accessed on July 25, 2018).</li><li><a class="nounderline abstract_t">Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014; 6:268ra179.</a></li><li><a class="nounderline abstract_t">Sebaaly J, Bowers L, Mazur J, et al. Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis. J Allergy Clin Immunol Pract 2016; 4:352.</a></li><li><a class="nounderline abstract_t">Argula RG, Kokosi M, Lo P, et al. A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis. Ann Am Thorac Soc 2016; 13:342.</a></li><li><a class="nounderline abstract_t">Gopalakrishnan V, Yao J, Steagall WK, et al. Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis. Chest 2019; 155:962.</a></li><li><a class="nounderline abstract_t">Kim C, Do KH, Cha J, et al. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study. Eur Radiol 2020; 30:735.</a></li><li><a class="nounderline abstract_t">Schmithorst VJ, Altes TA, Young LR, et al. Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis. AJR Am J Roentgenol 2009; 192:1037.</a></li><li><a class="nounderline abstract_t">Hirose M, Matsumuro A, Arai T, et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS One 2019; 14:e0212776.</a></li><li><a class="nounderline abstract_t">Gupta N, Hagner M, Wu H, et al. Serum Vascular Endothelial Growth Factor C as a Marker of Therapeutic Response to Sirolimus in Lymphangioleiomyomatosis. Ann Am Thorac Soc 2021; 18:174.</a></li><li><a class="nounderline abstract_t">Glasgow CG, Pacheco-Rodriguez G, Steagall WK, et al. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis. Chest 2018; 153:339.</a></li><li><a class="nounderline abstract_t">Lamattina AM, Taveira-Dasilva A, Goldberg HJ, et al. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. Chest 2018; 154:1070.</a></li><li><a class="nounderline abstract_t">Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005; 14:313.</a></li><li><a class="nounderline abstract_t">Goldberg HJ, Harari S, Cottin V, et al. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. Eur Respir J 2015; 46:783.</a></li><li><a class="nounderline abstract_t">Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant 2016; 31:111.</a></li><li><a class="nounderline abstract_t">Lu C, Lee HS, Pappas GP, et al. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis. Ann Am Thorac Soc 2017; 14:919.</a></li><li><a class="nounderline abstract_t">El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, et al. Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial. Chest 2017; 151:1302.</a></li><li><a class="nounderline abstract_t">Chang WY, Cane JL, Kumaran M, et al. A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J 2014; 43:1114.</a></li><li><a class="nounderline abstract_t">El-Chemaly S, Taveira-DaSilva A, Bagwe S, et al. Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial. Eur Respir J 2020; 55.</a></li><li><a class="nounderline abstract_t">Krymskaya VP, Courtwright AM, Fleck V, et al. A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex. Respir Med 2020; 163:105898.</a></li><li><a class="nounderline abstract_t">Gupta N, Zhang B, Zhou Y, et al. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis. Chest 2023; 163:1144.</a></li><li><a class="nounderline abstract_t">Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med 2017; 196:1337.</a></li><li><a class="nounderline abstract_t">Khawar MU, Yazdani D, Zhu Z, et al. Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis. J Heart Lung Transplant 2019; 38:949.</a></li><li><a class="nounderline abstract_t">Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996; 335:1275.</a></li><li><a class="nounderline abstract_t">Kpodonu J, Massad MG, Chaer RA, et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant 2005; 24:1247.</a></li><li><a class="nounderline abstract_t">Pechet TT, Meyers BF, Guthrie TJ, et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant 2004; 23:301.</a></li><li><a class="nounderline abstract_t">Maurer JR, Ryu J, Beck G, et al. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry. J Heart Lung Transplant 2007; 26:1293.</a></li><li><a class="nounderline abstract_t">Benden C, Rea F, Behr J, et al. Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant 2009; 28:1.</a></li><li><a class="nounderline abstract_t">Nine JS, Yousem SA, Paradis IL, et al. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant 1994; 13:714.</a></li><li><a class="nounderline abstract_t">Collins J, Müller NL, Kazerooni EA, et al. Lung transplantation for lymphangioleiomyomatosis: role of imaging in the assessment of complications related to the underlying disease. Radiology 1999; 210:325.</a></li><li><a class="nounderline abstract_t">Nakagiri T, Shintani Y, Minami M, et al. Lung Transplantation for Lymphangioleiomyomatosis in a Single Japanese Institute, With a Focus on Late-onset Complications. Transplant Proc 2015; 47:1977.</a></li><li><a class="nounderline abstract_t">Ussavarungsi K, Hu X, Scott JP, et al. Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis. Respir Med 2015; 109:1354.</a></li><li><a class="nounderline abstract_t">Reynaud-Gaubert M, Mornex JF, Mal H, et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation 2008; 86:515.</a></li><li><a class="nounderline abstract_t">Ando K, Okada Y, Akiba M, et al. Lung Transplantation for Lymphangioleiomyomatosis in Japan. PLoS One 2016; 11:e0146749.</a></li><li><a class="nounderline abstract_t">Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003; 167:976.</a></li><li><a class="nounderline abstract_t">Zaki KS, Aryan Z, Mehta AC, et al. Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation. World J Transplant 2016; 6:249.</a></li><li><a class="nounderline abstract_t">Gupta N, Han MK, McCormack FX. Regional Sparing in an Oligemic Lung Segment Supports Hematogenous Spread as a Pathogenic Mechanism in Lymphangioleiomyomatosis. Ann Am Thorac Soc 2015; 12:1247.</a></li><li><a class="nounderline abstract_t">Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004; 23:632.</a></li><li><a class="nounderline abstract_t">King-Biggs MB, Dunitz JM, Park SJ, et al. Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation 2003; 75:1437.</a></li><li><a class="nounderline abstract_t">El-Chemaly S, Goldberg HJ, Glanville AR. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation? Expert Rev Respir Med 2014; 8:657.</a></li><li><a class="nounderline abstract_t">Malouf MA, Hopkins P, Snell G, et al. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology 2011; 16:776.</a></li><li><a class="nounderline abstract_t">Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40:1349.</a></li><li><a class="nounderline abstract_t">Warrior K, Leard LE, Nair AR, et al. A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant. Respir Med 2022; 195:106779.</a></li><li><a class="nounderline abstract_t">Egan JJ, Remund KF, Corris P. Sirolimus for lymphangioleiomyomatosis lesions. N Engl J Med 2008; 358:1963.</a></li><li><a class="nounderline abstract_t">Glanville AR, Aboyoun C, Klepetko W, et al. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation. J Heart Lung Transplant 2015; 34:16.</a></li><li><a class="nounderline abstract_t">Ito T, Suno M, Sakamoto K, et al. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report. Transplant Proc 2016; 48:271.</a></li><li><a class="nounderline abstract_t">Ohara T, Oto T, Miyoshi K, et al. Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis. Ann Thorac Surg 2008; 86:e7.</a></li><li><a class="nounderline abstract_t">Almoosa KF, Ryu JH, Mendez J, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 2006; 129:1274.</a></li><li><a class="nounderline abstract_t">Hayashida M, Seyama K, Inoue Y, et al. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 2007; 12:523.</a></li><li><a class="nounderline abstract_t">Young LR, Almoosa KF, Pollock-Barziv S, et al. Patient perspectives on management of pneumothorax in lymphangioleiomyomatosis. Chest 2006; 129:1267.</a></li><li><a class="nounderline abstract_t">Roberts ME, Rahman NM, Maskell NA, et al. British Thoracic Society Guideline for pleural disease. Thorax 2023; 78:s1.</a></li><li><a class="nounderline abstract_t">Baumann MH, Strange C, Heffner JE, et al. Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 2001; 119:590.</a></li><li><a class="nounderline abstract_t">Hagaman JT, Schauer DP, McCormack FX, Kinder BW. Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective. Am J Respir Crit Care Med 2010; 181:1376.</a></li><li><a class="nounderline abstract_t">Gupta N, Langenderfer D, McCormack FX, et al. Chest Computed Tomographic Image Screening for Cystic Lung Diseases in Patients with Spontaneous Pneumothorax Is Cost Effective. Ann Am Thorac Soc 2017; 14:17.</a></li><li><a class="nounderline abstract_t">Suter A, Müller ME, Daccord C, et al. Probability of sporadic lymphangioleiomyomatosis in women presenting with spontaneous pneumothorax. Orphanet J Rare Dis 2023; 18:180.</a></li><li><a class="nounderline abstract_t">Cortinas N, Liu J, Kopras E, et al. Impact of Age, Menopause, and Sirolimus on Spontaneous Pneumothoraces in Lymphangioleiomyomatosis. Chest 2022; 162:1324.</a></li><li><a class="nounderline abstract_t">Sakurai T, Arai T, Hirose M, et al. Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis. Orphanet J Rare Dis 2021; 16:466.</a></li><li><a class="nounderline abstract_t">Zhou L, Ouyang R, Luo H, et al. Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series. Orphanet J Rare Dis 2018; 13:168.</a></li><li><a class="nounderline abstract_t">Ellender CM, Williams TJ, Gooi J, et al. Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis. Respirol Case Rep 2015; 3:72.</a></li><li><a class="nounderline abstract_t">Barrera P, Simons SO, Luijk B, et al. Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis. Ann Am Thorac Soc 2013; 10:408.</a></li><li><a class="nounderline abstract_t">Rozenberg D, Thenganatt J. Dramatic response to sirolimus in lymphangioleiomyomatosis. Can Respir J 2013; 20:413.</a></li><li><a class="nounderline abstract_t">Hecimovic A, Jakopovic M, Pavlisa G, et al. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS. Lymphology 2015; 48:97.</a></li><li><a class="nounderline abstract_t">Freitas CS, Baldi BG, Araújo MS, et al. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations. J Bras Pneumol 2015; 41:275.</a></li><li><a class="nounderline abstract_t">Itkin M, McCormack FX. Nonmalignant Adult Thoracic Lymphatic Disorders. Clin Chest Med 2016; 37:409.</a></li><li><a class="nounderline abstract_t">Fremont RD, Milstone AP, Light RW, Ninan M. Chylothoraces after lung transplantation for lymphangioleiomyomatosis: review of the literature and utilization of a pleurovenous shunt. J Heart Lung Transplant 2007; 26:953.</a></li><li><a class="nounderline abstract_t">Lefrou L, d'Alteroche L, Harchaoui Y, et al. Peritoneovenous shunt after failure of octreotide treatment for chylous ascites in lymphangioleiomyomatosis. Dig Dis Sci 2007; 52:3188.</a></li><li><a class="nounderline abstract_t">Paul S, Su S, Edenfield H, et al. Treatment of refractory lymphangioleiomyomatosis-associated chylous effusion with a pleuroperitoneal window and omental flap. J Thorac Cardiovasc Surg 2009; 138:497.</a></li><li><a class="nounderline abstract_t">Terzi A, Magnanelli G, Furlan G, Norsa A. [Pulmonary lymphangioleiomyomatosis. Case report]. Minerva Chir 1994; 49:1009.</a></li><li><a class="nounderline abstract_t">Basnet A, Shaaban H, Kessler W. A case of recurrent retroperitoneal lymphangioleiomyomatosis treated with progesterone therapy. Urol Ann 2015; 7:127.</a></li><li><a class="nounderline abstract_t">Oishi H, Hoshikawa Y, Sado T, et al. A Case of Successful Therapy by Intrapleural Injection of Fibrin Glue for Chylothorax after Lung Transplantation for Lymphangioleiomyomatosis. Ann Thorac Cardiovasc Surg 2017; 23:40.</a></li><li><a class="nounderline abstract_t">Mohammadieh AM, Bowler SD, Silverstone EJ, et al. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis. Med J Aust 2013; 199:121.</a></li><li><a class="nounderline abstract_t">Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49:255.</a></li><li><a class="nounderline abstract_t">Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology 2007; 242:277.</a></li><li><a class="nounderline abstract_t">Ciftci AO, Sanlialp I, Tanyel FC, Buyukpamukçu N. The association of pulmonary lymphangioleiomyomatosis with renal and hepatic angiomyolipomas in a prepubertal girl: a previously unreported entity. Respiration 2007; 74:335.</a></li><li><a class="nounderline abstract_t">Kim NR, Chung MP, Park CK, et al. Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man. Pathol Int 2003; 53:231.</a></li><li><a class="nounderline abstract_t">Baldi BG, Radzikowska E, Cottin V, et al. COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition. Chest 2022; 161:1589.</a></li><li><a class="nounderline abstract_t">Cottin V, Harari S, Humbert M, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012; 40:630.</a></li><li><a class="nounderline abstract_t">Sonaglioni A, Baravelli M, Cassandro R, et al. Hemodynamic Mechanisms of Exercise-Induced Pulmonary Hypertension in Patients with Lymphangioleiomyomatosis: The Role of Exercise Stress Echocardiography. J Am Soc Echocardiogr 2018; 31:888.</a></li><li><a class="nounderline abstract_t">Zafar MA, McCormack FX, Rahman S, et al. Pulmonary vascular shunts in exercise-intolerant patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med 2013; 188:1167.</a></li><li><a class="nounderline abstract_t">Taveira-DaSilva AM, Jones AM, Julien-Williams PA, et al. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis. Chest 2015; 147:180.</a></li><li><a class="nounderline abstract_t">Pimenta SP, Baldi BG, Acencio MM, et al. Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade. J Bras Pneumol 2011; 37:424.</a></li><li><a class="nounderline abstract_t">Pimenta SP, Baldi BG, Kairalla RA, Carvalho CR. Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response. J Bras Pneumol 2013; 39:5.</a></li><li><a class="nounderline abstract_t">Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006; 354:2621.</a></li><li><a class="nounderline abstract_t">Baldi BG, Ribeiro Carvalho CR. Doxycycline in lymphangioleiomyomatosis: not all questions are answered. Eur Respir J 2014; 43:1536.</a></li><li><a class="nounderline abstract_t">Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangioleiomyomatosis. A meta-analysis. Chest 1989; 96:1352.</a></li><li><a class="nounderline abstract_t">Urban T, Kuttenn F, Gompel A, et al. Pulmonary lymphangiomyomatosis. Follow-up and long-term outcome with antiestrogen therapy; a report of eight cases. Chest 1992; 102:472.</a></li><li><a class="nounderline abstract_t">Schiavina M, Contini P, Fabiani A, et al. Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients. Sarcoidosis Vasc Diffuse Lung Dis 2007; 24:39.</a></li><li><a class="nounderline abstract_t">Taveira-DaSilva AM, Stylianou MP, Hedin CJ, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126:1867.</a></li><li><a class="nounderline abstract_t">Rossi GA, Balbi B, Oddera S, et al. Response to treatment with an analog of the luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis 1991; 143:174.</a></li><li><a class="nounderline abstract_t">Banner AS, Carrington CB, Emory WB, et al. Efficacy of oophorectomy in lymphangioleiomyomatosis and benign metastasizing leiomyoma. N Engl J Med 1981; 305:204.</a></li><li><a class="nounderline abstract_t">Urban T, Lazor R, Lacronique J, et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 1999; 78:321.</a></li><li><a class="nounderline abstract_t">Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160:628.</a></li><li><a class="nounderline abstract_t">Harari S, Cassandro R, Chiodini I, et al. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest 2008; 133:448.</a></li><li><a class="nounderline abstract_t">Shaw BM, Kopras E, Gupta N. Menstrual Cycle-related Respiratory Symptom Variability in Patients with Lymphangioleiomyomatosis. Ann Am Thorac Soc 2022; 19:1619.</a></li><li><a class="nounderline abstract_t">Baldi BG, Freitas CS, Araujo MS, et al. Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31:129.</a></li><li><a class="nounderline abstract_t">Hayashida M, Yasuo M, Hanaoka M, et al. Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database. Respir Investig 2016; 54:193.</a></li><li><a class="nounderline abstract_t">Gupta, Nishant; Lee, Hye-Seung; Ryu, et al. The NHLBI LAM Registry: Prognostic physiological and radiological biomarkers emerge from a 15-year prospective longitudinal analysis (accepted for publication). Chest 2018.</a></li><li><a class="nounderline abstract_t">Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323:1254.</a></li><li><a class="nounderline abstract_t">Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151:527.</a></li><li><a class="nounderline abstract_t">Oprescu N, McCormack FX, Byrnes S, Kinder BW. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry. Lung 2013; 191:35.</a></li><li><a class="nounderline abstract_t">Bee J, Bhatt R, McCafferty I, Johnson SR. A 4-year prospective evaluation of protocols to improve clinical outcomes for patients with lymphangioleiomyomatosis in a national clinical centre. Thorax 2015; 70:1202.</a></li><li><a class="nounderline abstract_t">Johnson SR, Whale CI, Hubbard RB, et al. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 2004; 59:800.</a></li><li><a class="nounderline abstract_t">Reid JK, Rees H, Cockcroft D. Long term survival in a patient with pulmonary lymphangioleiomyomatosis. Can Respir J 2002; 9:342.</a></li><li><a class="nounderline abstract_t">Yigla M, Bentur L, Ben Izhak O, Rubin AH. Pulmonary lymphangioleiomyomatosis: prolonged survival despite multiple pregnancies and no hormonal intervention. Respirology 1996; 1:213.</a></li><li><a class="nounderline abstract_t">Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 2001; 25:479.</a></li><li><a class="nounderline abstract_t">Taveira-DaSilva AM, Jones AM, Julien-Williams P, et al. Severity and outcome of cystic lung disease in women with tuberous sclerosis complex. Eur Respir J 2015; 45:171.</a></li><li><a class="nounderline abstract_t">Taveira-DaSilva AM, Steagall WK, Rabel A, et al. Reversible airflow obstruction in lymphangioleiomyomatosis. Chest 2009; 136:1596.</a></li><li><a class="nounderline abstract_t">Crausman RS, Lynch DA, Mortenson RL, et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest 1996; 109:131.</a></li><li><a class="nounderline abstract_t">Lo P, Brown MS, Kim H, et al. Cyst-based measurements for assessing lymphangioleiomyomatosis in computed tomography. Med Phys 2015; 42:2287.</a></li><li><a class="nounderline abstract_t">Baldi BG, Araujo MS, Freitas CS, et al. Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM). Lung 2014; 192:967.</a></li></ol></div><div id="topicVersionRevision">Topic 107652 Version 39.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20044458" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27628078" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22217496" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sleep desaturation and its relationship to lung function, exercise and quality of life in LAM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26968971" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26917604" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24312387" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Soy, red clover, and isoflavones and breast cancer: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11587999" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18628234" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Variability in the prevalence of acute bronchoresponsiveness in different populations of patients with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24064347" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A pilot study assessing the effect of bronchodilator on dynamic hyperinflation in LAM.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19318672" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17040934" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Air travel in women with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30545392" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Air travel and incidence of pneumothorax in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34794166" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-dependent Breast Cancer: Clinical Consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11083892" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical experience of lymphangioleiomyomatosis in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15209123" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Conservative management of pulmonary lymphangioleiomyomatosis and tuberous sclerosis complicated by renal angiomyolipomas in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8775689" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909861" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pregnancy unmasking lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433165" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pregnancy complicated with pulmonary lymphangioleiomyomatosis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15676319" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pregnancy and lymphangioleiomyomatosis: anaesthetic management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117742" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pregnancy experiences among women with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996772" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : [Renal angiomyolipoma rupture during pregnancy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449160" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Conservative management of a bleeding renal angiomyolipoma in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15696353" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Embolization of a bleeding renal angiomyolipoma in pregnancy: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37451227" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Spontaneous pneumothoraces during pregnancy in patients with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210669" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32788260" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454306" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3032524" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11771497" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Lymphangioleiomyomatosis. A series of three case reports illustrating the link with high oestrogen states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12639372" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26422572" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Long-term stable lung function and second uncomplicated pregnancy on sirolimus in lymphangioleiomyomatosis (LAM).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22117507" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Successful pregnancy complicated by persistent pneumothorax in a patient with lymphangioleiomyomatosis (LAM) on sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15686735" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Absence of teratogenicity of sirolimus used during early pregnancy in a liver transplant recipient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24051985" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639436" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27502989" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27103385" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Should lymphangioleiomyomatosis patients be permitted to donate blood?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37087906" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : French recommendations for the diagnosis and management of lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35710743" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Disease monitoring using lung function trajectory in lymphangioleiomyomatosis: assessment in two national cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36610667" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21714641" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reduced lung-cancer mortality with low-dose computed tomographic screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30291925" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Chest CT Scan at Radiation Dose of a Posteroanterior and Lateral Chest Radiograph Series: A Proof of Principle in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24159565" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26386638" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30846465" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30846465" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21410393" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy and safety of sirolimus in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23978644" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and safety of low-dose sirolimus for treatment of lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20833822" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15780099" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690594" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25329516" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25496098" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Chronic sirolimus therapy for lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27513278" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184959" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22896596" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18184971" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21915260" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28993539" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36801466" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Determinants of Progression and Mortality in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22266380" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Radical reduction of smooth muscle cells in explanted lung of a LAM patient treated with sirolimus: first case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21600034" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21890398" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical presentation and management of mTOR inhibitor-associated stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24295418" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mammalian target of rapamycin inhibitor-associated stomatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Sirolimus for the treatment of lymphangioleiomyomatosis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23307976" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Everolimus causing severe hypertriglyceridemia and acute pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28096282" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28096282" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25540326" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : mTOR inhibition improves immune function in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26725158" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26799509" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30660784" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Use of CT Imaging to Quantify Progression and Response to Treatment in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31471750" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19304711" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30818375" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32795223" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Serum Vascular Endothelial Growth Factor C as a Marker of Therapeutic Response to Sirolimus in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28576630" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30144422" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15833062" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Inhibitors of the mammalian target of rapamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26113676" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26156073" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28570161" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28192114" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311763" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32060062" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Celecoxib in lymphangioleiomyomatosis: results of a phase I clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32125970" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36642366" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29140122" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31303421" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8857007" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Lung transplantation for lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16143241" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15019639" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Lung transplantation for lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18096481" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19134523" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lung transplantation for lymphangioleiomyomatosis: the European experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947889" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Lymphangioleiomyomatosis: recurrence after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10207410" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Lung transplantation for lymphangioleiomyomatosis: role of imaging in the assessment of complications related to the underlying disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293084" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Lung Transplantation for Lymphangioleiomyomatosis in a Single Japanese Institute, With a Focus on Late-onset Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26321137" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18724219" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Lung transplantation for lymphangioleiomyomatosis: the French experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26771878" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Lung Transplantation for Lymphangioleiomyomatosis in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12411287" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27011924" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26317276" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Regional Sparing in an Oligemic Lung Segment Supports Hematogenous Spread as a Pathogenic Mechanism in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15135383" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792493" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25199529" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21362103" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34419372" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35276437" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18450609" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Sirolimus for lymphangioleiomyomatosis lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25049068" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26915883" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19021963" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Sirolimus ameliorated post lung transplant chylothorax in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685019" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17587419" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16685018" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Patient perspectives on management of pneumothorax in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37433578" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : British Thoracic Society Guideline for pleural disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11171742" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20167846" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737563" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Chest Computed Tomographic Image Screening for Cystic Lung Diseases in Patients with Spontaneous Pneumothorax Is Cost Effective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37415209" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Probability of sporadic lymphangioleiomyomatosis in women presenting with spontaneous pneumothorax.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35660029" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Impact of Age, Menopause, and Sirolimus on Spontaneous Pneumothoraces in Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34732225" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Reduced risk of recurrent pneumothorax for sirolimus therapy after surgical pleural covering of entire lung in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30241551" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26090116" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Management of refractory chylothorax in pulmonary lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23952870" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Efficacy of sirolimus therapy for chylous effusions in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24137571" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Dramatic response to sirolimus in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26714374" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26176526" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27514588" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Nonmalignant Adult Thoracic Lymphatic Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17845935" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Chylothoraces after lung transplantation for lymphangioleiomyomatosis: review of the literature and utilization of a pleurovenous shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638079" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Peritoneovenous shunt after failure of octreotide treatment for chylous ascites in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19619804" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Treatment of refractory lymphangioleiomyomatosis-associated chylous effusion with a pleuroperitoneal window and omental flap.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7808656" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : [Pulmonary lymphangioleiomyomatosis. Case report].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25657565" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : A case of recurrent retroperitoneal lymphangioleiomyomatosis treated with progesterone therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27431923" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A Case of Successful Therapy by Intrapleural Injection of Fibrin Glue for Chylothorax after Lung Transplantation for Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23879512" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24053983" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17105849" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15988170" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : The association of pulmonary lymphangioleiomyomatosis with renal and hepatic angiomyolipomas in a prepubertal girl: a previously unreported entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12675767" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34942174" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : COVID-19 in Lymphangioleiomyomatosis: An International Study of Outcomes and Impact of Mechanistic Target of Rapamycin Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22362861" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29605474" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Hemodynamic Mechanisms of Exercise-Induced Pulmonary Hypertension in Patients with Lymphangioleiomyomatosis: The Role of Exercise Stress Echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24180449" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Pulmonary vascular shunts in exercise-intolerant patients with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25167325" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881731" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23503480" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16775248" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24789959" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Doxycycline in lymphangioleiomyomatosis: not all questions are answered.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2582843" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Treatment of lymphangioleiomyomatosis. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1643935" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Pulmonary lymphangiomyomatosis. Follow-up and long-term outcome with antiestrogen therapy; a report of eight cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18069418" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596686" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1824744" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Response to treatment with an analog of the luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7242600" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Efficacy of oophorectomy in lymphangioleiomyomatosis and benign metastasizing leiomyoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10499073" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430739" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071009" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35649208" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Menstrual Cycle-related Respiratory Symptom Variability in Patients with Lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25078640" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Clinical course and characterisation of lymphangioleiomyomatosis in a Brazilian reference centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27108015" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Reductions in pulmonary function detected in patients with lymphangioleiomyomatosis: An analysis of the Japanese National Research Project on Intractable Diseases database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : The NHLBI LAM Registry: Prognostic physiological and radiological biomarkers emerge from a 15-year prospective longitudinal analysis (accepted for publication)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2215609" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Lymphangioleiomyomatosis. Clinical course in 32 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842216" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23007140" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26123659" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : A 4-year prospective evaluation of protocols to improve clinical outcomes for patients with lymphangioleiomyomatosis in a national clinical centre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333859" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Survival and disease progression in UK patients with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12410326" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Long term survival in a patient with pulmonary lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9424399" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Pulmonary lymphangioleiomyomatosis: prolonged survival despite multiple pregnancies and no hormonal intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11257622" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25537563" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Severity and outcome of cystic lung disease in women with tuberous sclerosis complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19447921" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Reversible airflow obstruction in lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549175" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25979023" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Cyst-based measurements for assessing lymphangioleiomyomatosis in computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25201087" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
